Original Article
Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography
N Engl J Med 2000; 343:254-261July 27, 2000
- Abstract
Background
Determining the stage of non–small-cell lung cancer often requires multiple preoperative tests and invasive procedures. Whole-body positron-emission tomography (PET) may simplify and improve the evaluation of patients with this tumor.
Methods
We prospectively compared the ability of a standard approach to staging (computed tomography [CT], ultrasonography, bone scanning, and, when indicated, needle biopsies) and one involving PET to detect metastases in mediastinal lymph nodes and at distant sites in 102 patients with resectable non–small-cell lung cancer. The presence of mediastinal metastatic disease was confirmed histopathologically. Distant metastases that were detected by PET were further evaluated by standard imaging tests and biopsies. Patients were followed postoperatively for six months by standard methods to detect occult metastases. Logistic-regression analysis was used to evaluate the ability of PET and CT to identify malignant mediastinal lymph nodes.
Results
The sensitivity and specificity of PET for the detection of mediastinal metastases were 91 percent (95 percent confidence interval, 81 to 100 percent) and 86 percent (95 percent confidence interval, 78 to 94 percent), respectively. The corresponding values for CT were 75 percent (95 percent confidence interval, 60 to 90 percent) and 66 percent (95 percent confidence interval, 55 to 77 percent). When the results of PET and CT were adjusted for each other, only PET results were positively correlated with the histopathological findings in mediastinal lymph nodes (P<0.001). PET identified distant metastases that had not been found by standard methods in 11 of 102 patients. The sensitivity and specificity of PET for the detection of both mediastinal and distant metastatic disease were 95 percent (95 percent confidence interval, 88 to 100 percent) and 83 percent (95 percent confidence interval, 74 to 92 percent), respectively. The use of PET for clinical staging resulted in a different stage from the one determined by standard methods in 62 patients: the stage was lowered in 20 and raised in 42.
Conclusions
PET improves the rate of detection of local and distant metastases in patients with non–small-cell lung cancer.
Media in This Article
Figure 2
CT and PET Findings in a Centrally Located Adenocarcinoma of the Left Lung and a Small Pretracheal Lymph Node in a Patient with Non–Small-Cell Lung Cancer.Figure 3
Preoperative Axial CT and PET Findings in a Patient with Non–Small-Cell Lung Cancer.Article Activity
- Article
The occurrence of distant metastases and metastases to mediastinal lymph nodes profoundly affects the prognosis of non–small-cell lung cancer, making accurate staging crucial for selecting appropriate treatment. When used alone, the results of most staging methods, such as computed tomography (CT), ultrasonography, and radionuclide bone scanning, are far from ideal. Whole-body positron-emission tomography (PET) with 18F-fluorodeoxyglucose (fludeoxyglucose F 18) as a tracer is a new metabolic imaging technique that relies on the fact that there is increased metabolism of glucose in tumor cells.1,2 Pulmonary tumors actively metabolize the tracer, and several studies have shown that the method has about 95 percent sensitivity for detecting primary bronchial tumors3,4 and mediastinal lymph-node metastases.5-7 Within the body, the method has a lower limit of resolution of 1 to 1.2 cm. The specificity of this method is not optimal, because the uptake of 18F-fluorodeoxyglucose is increased by the presence of inflammatory processes in the lungs. Another limitation is that histopathological verification of the results of the PET scan is often conducted only on “hot spots” (areas in which the uptake of 18F-fluorodeoxyglucose is much greater than the background uptake in all areas but the heart, brain, and urinary tract) and does not include lymph nodes whose uptake of the radioactive glucose is not increased. The use of PET to identify distant metastases in patients with non–small-cell lung cancer has been investigated in a few small studies.8,9 Therefore, we prospectively investigated the role of PET in evaluating the mediastinum and detecting distant metastases in such patients.
Methods
Patients
Patients with potentially resectable non–small-cell lung cancer who were being evaluated with standard tests and procedures in the outpatient department of pulmonary diseases at Groningen University Hospital in Groningen, the Netherlands, were eligible for the study. Patients were excluded if they had hyperglycemia (defined as a serum glucose level of more than 180 mg per deciliter [10 mmol per liter]) before the PET study, since in a pilot study, such levels seemed to affect the quality of the PET images adversely, or had undergone cervical mediastinoscopy or parasternal mediastinotomy. All patients were evaluated by means of a history taking, physical examination, blood count, measurement of electrolytes, tests of renal and liver function, bronchoscopy, cervical mediastinoscopy, and CT of the chest, including the upper abdomen. In patients with symptoms or signs suggestive of distant metastases, appropriate additional imaging tests and biopsies were performed. The combination of tests and invasive procedures leading to clinical classification according to the tumor–node–metastasis (TNM) staging system of the American Joint Committee on Cancer10 was considered traditional staging. Every two months for at least six months after thoracotomy, the patients underwent a physical examination and chest radiography (as well as additional tests in patients suspected of having distant metastases).
All patients gave written informed consent. The study was approved by the medical ethics committee of Groningen University Hospital.
Surgery
Cervical mediastinoscopies, parasternal mediastinotomies, and explorative thoracotomies were performed by four thoracic surgeons. Cervical mediastinoscopy was considered adequate when it included, at a minimum, biopsy specimens of the paratracheal and tracheobronchial lymph nodes on the right and left sides, and subcarinal lymph nodes. Mediastinal lymph nodes were dissected during thoracotomy, with thorough attention paid to the superior and inferior lymph nodes on the right side or the superior and inferior mediastinal and aortic lymph nodes on the left. Surgeons were strongly encouraged to dissect both normal-appearing lymph nodes and those that appeared enlarged on CT. Lymph nodes were labeled according to the classification of Mountain and Dresler11 and sent for histopathological examination, which included staining with hematoxylin and eosin.
Whole-Body PET
PET was performed with a scanner (ECAT model 951/31, Siemens/CTI, Knoxville, Tenn.) that had a field of view of 10.8 cm and a full width of 6 mm at half-maximal resolution. Data were reconstructed iteratively12 into coronal, sagittal, and transverse sections and a three-dimensional rotating projection. 18F-fluorodeoxyglucose was synthesized according to the method of Hamacher et al.13 by a high-performance liquid chromatography controlled-synthesis module.14 Patients were instructed to fast for six hours before the PET study, but they were allowed to drink water and to take their usual medications. 18F-fluorodeoxyglucose (370 MBq) was administered intravenously.
Before the prospective study, we performed a pilot study in seven patients with non–small-cell lung cancer to determine the optimal scanning protocol, especially with regard to the mediastinum. Static (i.e., isolated rather than dynamic) emission scans were performed 30, 60, 90, and 120 minutes after the injection of 18F-fluorodeoxyglucose. Imaging reconstruction was performed after 2.5, 5, 8, and 10 minutes in each position for both emission scans (which measure only 18F-fluorodeoxyglucose uptake) and transmission scans (source, germanium-68). The results of post-emission transmission scans were used to correct for attenuation of the 18F-fluorodeoxyglucose signal. The emission scans performed 90 minutes after the injection of 18F-fluorodeoxyglucose, with reconstructions made after eight minutes in each position, were considered to have provided the best images with respect to the extent of contrast between hot spots and the background level in mediastinal lymph-node levels. Both types of scans were performed from the level of the first cervical vertebra to the level of the fifth lumbar vertebra. All clinicians involved in the care of the patients were unaware of the results of PET.
CT of the Chest
CT of the chest and upper abdomen including the adrenal glands was performed with a 120-KV, 125-mA tomoscan (model SR 7000, Philips Medical Systems, Enthoven, the Netherlands) with a slice thickness of 10 mm and a scanning time of one second per slice. During CT, 200 ml of contrast medium (Omnipaque, iohexol, Nycomed, Amersham, Princeton, N.J.) was administered intravenously at a rate of 1.5 ml per second. In 13 patients no contrast medium was used.
Assessment of Metastases
Hot Spots Inside the Mediastinum
A positive PET scan was one that had at least one hot spot. All imaging studies were analyzed by two independent observers who were not aware of the patients' clinical data. If they could not reach a consensus, the opinion of a third observer was sought.
The gold standard for the diagnosis of mediastinal metastases is surgical exploration of the mediastinum and histopathological examination of mediastinal lymph-node compartments (stations). Because the degree of anatomical resolution of mediastinal lymph nodes with PET is limited, we broadened the lymph-node categories in the classification of Mountain and Dresler11 in order to compare the results of CT, PET, and histopathological analysis (Figure 1Figure 1
Mediastinal Lymph-Node Levels Used to Compare the Results of PET, CT, and Histopathological Analysis.). For the interpretation of the CT findings, the mediastinal lymph nodes were divided in two categories: those with a diameter of less than 1 cm in the shortest axis were considered normal in size and those with a diameter of 1 cm or more were considered to be enlarged.Hot Spots Outside the Mediastinum
Hot spots outside the mediastinum were described according to their anatomical locations and were related to data obtained by traditional staging methods, including the data obtained during the six-month follow-up in the case of lesions that had not been detected previously by traditional staging methods. If there was a clinical suspicion of distant metastases during the follow-up period, biopsies or imaging tests were performed. The results of PET were considered to be falsely positive if no metastases became apparent at a hot spot during follow-up.
Statistical Analysis
The study was designed to detect with a power of 0.85 and a two-sided α level of 0.05 a difference of 35 percent between the sensitivity of PET and that of CT (whose sensitivity was assumed to be 60 percent). In order to identify such a difference, the study required a minimum of 30 patients with mediastinal metastases. Assuming that mediastinal metastases are present in about 30 percent of patients with resectable non–small-cell lung cancer, a minimum of 100 patients had to be enrolled.
We determined the sensitivity, specificity, and diagnostic accuracy of each imaging method and of the combination of PET and CT.
The degree of agreement between observers was quantified with the kappa statistic. The two-sided sign test was used to compare the differences between the TNM class identified by PET and that identified by traditional methods of staging. Logistic-regression analysis was performed to evaluate the relative ability of PET and CT to identify metastatic cancer in mediastinal lymph nodes. A P value of less than 0.05 was considered to indicate statistical significance. Statistical analysis was carried out with SPSS software.
Results
Patients
Between September 1996 and December 1998, we evaluated 110 consecutive patients. Non–small-cell lung cancer was diagnosed in 102 patients: 58 had squamous-cell carcinoma, 28 had adenocarcinoma, 13 had large-cell carcinoma, 2 had adenosquamous carcinoma, and 1 had a neuroendocrine tumor. We excluded two patients with solitary metastases from melanoma and breast cancer, respectively; one with tuberculosis; one with sarcoidosis; and four in whom mediastinal dissection was inadequate. The characteristics of the 102 patients who were evaluated are shown in Table 1Table 1
Characteristics of the 102 Patients with Resectable Non–Small-Cell Lung Cancer Who Could Be Evaluated..Surgery
All patients underwent a cervical mediastinoscopy that explored lymph-node levels 1, 2, 3, and 5 (Figure 1). In patients who underwent a right-sided thoracotomy, mediastinal lymph nodes at levels 1, 2, 5, and 6 were dissected, and in those who underwent a left-sided thoracotomy, lymph nodes at levels 1, 3, 4, 5, and 7 were dissected. Six patients with solitary parenchymal metastasis were considered to have resectable tumors. In three patients with solitary brain metastases, curative lobectomy was performed after the removal of the brain lesion. In two patients with two primary tumors in two lobes of the same lung, a curative pneumonectomy was performed. One patient with a non–small-cell lung cancer of stage T2N2M1 had a double tumor and microscopic tumor invasion of the subcarinal lymph nodes, all three of which were completely resected. In the group as a whole, 97 percent of the mediastinal lymph-node levels that could be reached were dissected (Table 1). At each level a median of 7 separate lymph nodes (range, 1 to 18) were dissected. Histopathological analysis showed that a total of 37 mediastinal lymph-node levels contained metastatic tumor.
Detection of Primary Tumor with PET
Every primary tumor was detected as an intense hot spot on PET scans (Figure 2Figure 2
CT and PET Findings in a Centrally Located Adenocarcinoma of the Left Lung and a Small Pretracheal Lymph Node in a Patient with Non–Small-Cell Lung Cancer.). In one patient with two primary tumors, the squamous-cell carcinoma appeared as a hot spot on PET, but surprisingly, the adenocarcinoma was not detected, although it was clearly visualized on CT.Detection of Mediastinal Metastases with PET
Mediastinal lymph-node metastases were correctly detected by PET in 29 of 32 patients with positive results on histopathological analysis (Table 2Table 2
Results of CT, PET, and Histopathological Analyses of Mediastinal Lymph Nodes in Patients with Resectable Non–Small-Cell Lung Cancer.) and in 28 of the 37 mediastinal lymph-node levels that were positive for metastatic tumor on histopathological analysis. PET correctly identified 60 of 70 patients who did not have mediastinal lymph-node metastases on histopathological analysis (Table 2). Distinguishing between intrapulmonary involvement and mediastinal lymph-node involvement is an important part of the process of deciding whether thoracotomy should be performed. The sensitivity and specificity of PET for detecting mediastinal metastases were 91 percent (95 percent confidence interval, 81 to 100 percent) and 86 percent (95 percent confidence interval, 78 to 94 percent), respectively (Table 3Table 3
Sensitivity, Specificity, and Accuracy of CT, PET, and Both CT and PET as Compared with Histopathological Analysis for the Mediastinal Evaluation of Patients with Resectable Non–Small-Cell Lung Cancer.). The overall negative predictive value of the method was 95 percent (95 percent confidence interval, 90 to 100 percent), and the positive predictive value was 74 percent (95 percent confidence interval, 60 to 88 percent). Because of the presence of reactive hyperplasia in the mediastinal lymph nodes of seven patients and of silicoanthracosis in three, PET produced a false positive result. False negative results were due to microscopic-tumor residue in two patients and to the inability of the method to distinguish between paramediastinal primary tumor and mediastinal lymph nodes in one patient. The degree of interobserver agreement (kappa value) in detecting mediastinal hot spots was 0.87 (95 percent confidence interval, 0.64 to 1.0).Detection of Distant Metastases with PET
In 20 of 102 patients, 29 hot spots were detected outside the mediastinum (Figure 3Figure 3
Preoperative Axial CT and PET Findings in a Patient with Non–Small-Cell Lung Cancer.). Three malignant satellite nodules in the resected lobe were confirmed to be present during histologic examination, and 17 of the 29 hot spots were diagnosed as metastases during the follow-up period — 3 by means of biopsy, 5 on the basis of the detection of new, growing lesions on ultrasonography, 5 by means of CT, and 4 on the basis of a finding of lytic lesions on radiographic imaging. Nine hot spots — four in the colon, two in the lung, and one each in the liver, adrenal glands, and rib — were considered to be false positive results, since no metastases were identified in these areas during the follow-up period.PET correctly identified distant metastases in 11 of 102 patients (11 percent) in whom the usual methods of staging had found none. In three other patients, intrapulmonary metastases had been detected by CT. In three patients without hot spots, distant metastases developed during follow-up. No distant metastases were diagnosed during follow-up in 79 patients without hot spots on PET. The sensitivity and specificity of PET for detecting distant metastases alone were 82 percent (95 percent confidence interval, 64 to 100 percent) and 93 percent (95 percent confidence interval, 88 to 98 percent), respectively. The degree of interobserver agreement was 0.98 (95 percent confidence interval, 0.73 to 1.0).
CT of the Chest
In 20 of the 37 lymph-node levels that were positive for metastatic tumor on histopathological analysis, CT revealed enlarged mediastinal lymph nodes. CT correctly identified 46 of 70 patients who did not have mediastinal metastases on histopathological analysis and 24 of 32 patients who did have mediastinal metastases (Table 2). In eight patients with mediastinal lymph-node metastases, the size of the lymph nodes was normal. The sensitivity of CT was 75 percent (95 percent confidence interval, 60 to 90 percent), and the specificity was 66 percent (95 percent confidence interval, 55 to 77 percent). An example of a mediastinal metastasis that was identified as a hot spot on PET but was deemed normal on CT is shown in Figure 4Figure 4
CT and PET Findings in a Patient with Squamous-Cell Carcinoma of the Right Lung..Overall Prognostic Value of PET
The overall sensitivity and specificity of PET, as compared with histopathological analysis, in detecting mediastinal and distant metastatic disease were 95 percent (95 percent confidence interval, 88 to 100 percent) and 83 percent (95 percent confidence interval, 74 to 92 percent), respectively. Logistic-regression analysis revealed that the results of both PET and CT were significantly correlated with the results of histopathological analysis. When adjusted for each other, however, the correlation remained significant only for PET (P<0.001). The use of PET for clinical staging resulted in a different stage from the one arrived at by the usual methods in 62 of 102 patients. In 20 patients the stage determined by PET was lower, and in 42 patients it was higher (P<0.01 by the two-sided sign test).
Discussion
The ability of PET to identify tumors depends primarily on the degree of uptake of 18F-fluorodeoxyglucose by malignant cells, the size of the tumor, and the presence or absence of inflammation. Non–small-cell lung-cancer cells avidly incorporate 18F-fluorodeoxyglucose because they have an increased rate of glycolysis and overexpress the glucose transporter.15 At presentation, most non–small-cell lung cancers are large enough to have hot spots on PET scans. Inflammation from an obstructing endobronchial tumor or other inflammatory processes cause most of the false positive hot spots on PET scans. Previous studies have found that PET has good sensitivity and specificity for detecting mediastinal lymph-node metastases, but some of these investigations did not report to what extent surgical exploration was used to confirm the presence of such metastases.5,6,16 The sensitivity and specificity of this method can be misleadingly high if a biopsy of normal-sized lymph nodes with minimal tumor is not performed. To relate PET data to histopathological data, both normal-appearing and abnormal-appearing lymph nodes must undergo biopsy or be removed for further examination. In our study, 97 percent of the mediastinal lymph-node levels that could be reached surgically were dissected and underwent histopathological analysis.
A disadvantage of PET is its limited anatomical resolution, which makes assessment of the extent of the primary tumor, especially if it invades the mediastinum, unreliable. For the same reason, mediastinal hot spots can be related only to lymph-node levels and not to individual lymph nodes. We defined these levels during the preliminary part of the study to facilitate the interpretation of distinct hot spots in the mediastinum.
Another problem with PET is that 18F-fluorodeoxyglucose accumulates as part of the physiologic process in the brain and urinary tract, which makes an evaluation of metastases at these sites difficult. A qualitative analysis of PET images can serve only to rule out the presence of such metastases and not to identify them.7,17 This point brings the usefulness of transmission scanning for this purpose into question, although the results of mediastinal and hepatic scanning are slightly improved after correction for attenuation of the 18F-fluorodeoxyglucose signal. The use of CT together with PET may help to pinpoint the anatomical location of the hot spot, especially in the case of intrapulmonary lymph nodes, which are located close to the mediastinum and thus can be mistaken for mediastinal lymph nodes.18 However, in one study, computerized fusion of the two types of images seemed to be only marginally more beneficial than simple visual correlation of the PET scan and CT scan in terms of pinpointing metastases in thoracic lymph nodes.19 We also found that combining CT with PET did not significantly improve sensitivity and specificity.
The high negative predictive value of PET for mediastinal lymph-node metastases can be used to advantage in the approach to patients with non–small-cell lung cancer, because invasive procedures are probably not necessary in a patient with negative findings on PET in the mediastinum. However, our finding of a positive predictive value of 74 percent means that patients in whom a mediastinal hot spot is found on PET will need to undergo a cervical mediastinoscopy as part of the workup for non–small-cell lung cancer. The positive predictive value will be lower in patients with inflammatory changes.20,21
Frequent sites of distant metastasis in patients with non–small-cell lung cancer are the liver, adrenal glands, bone, and brain. Whole-body PET can replace other types of imaging for all these sites except the brain, where the degree of uptake of 18F-fluorodeoxyglucose lacks specificity. The use of PET to identify distant metastases in patients with non–small-cell lung cancer has not been extensively studied, but the method may offer better results for bone metastases than bone scanning.8 If we had not also performed invasive procedures in our study, 17 percent of patients would have been denied potentially curative surgery because of false positive mediastinal or distant hot spots or both. For this reason, a positive PET result requires an evaluation involving mediastinoscopy and, if indicated for distant lesions, additional procedures.
Our study confirms that, as compared with traditional staging methods, PET can result in a more accurate classification of the stage of disease in patients with resectable non–small-cell lung cancer. The increased accuracy may improve survival, but this outcome was not the primary end point of our study. Therefore, a randomized study is necessary to determine whether a diagnostic strategy that includes PET can improve survival. However, some small studies have suggested that the use of standardized uptake values for the primary tumor has independent prognostic value.22,23
Concurrent detection of mediastinal and distant metastases by 18F-fluorodeoxyglucose PET will decrease the number of tests and invasive procedures required in the evaluation of patients with non–small-cell lung cancer. Implementing PET at the start of the staging process may improve the efficiency of the workup, but at this time the procedure is not cost effective, given the limited availability of dedicated PET cameras.
Presented in part at the International Conference of the American Thoracic Society–American Lung Association, San Diego, Calif., April 23–28, 1999, and at the Annual Meeting of the American Society of Clinical Oncology, Atlanta, May 15–18, 1999.
Supported by a grant for data management from Groningen University Hospital.
Source Information
From the Departments of Pulmonary Diseases (R.M.P., J.W.G.P., G.H.K., H.J.M.G.), Thoracic Surgery (J.J.M.), Radiology (E.L.M.), and Biostatistics and Epidemiology (V.F.) and the Positron-Emission Tomography Center (R.M.P., W.V., J.P.), Groningen University Hospital, Groningen, the Netherlands.
Address reprint requests to Dr. Groen at the Department of Pulmonary Diseases, Groningen University Hospital, Hanzeplein 1, 9700 RB Groningen, the Netherlands, or at h.j.m.groen@int.azg.nl.
- References
References
1
Dahlbom M ,Hoffman EJ ,Hoh CK , et al. Whole-body positron emission tomography. I. Methods and performance characteristics. J Nucl Med 1992;33:1191-1199
Web of Science | Medline2
Nolop KB ,Rhodes CG ,Brudin LH , et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987;60:2682-2689
CrossRef | Web of Science | Medline3
Sazon DAD ,Santiago SM ,Soo Hoo GW , et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-421
Web of Science | Medline4
Dewan NA ,Gupta NC ,Redepenning LS ,Phalen JJ ,Frick MP . Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: potential role in evaluation and management. Chest 1993;104:997-1002
CrossRef | Web of Science | Medline5
Chin R Jr ,Ward R ,Keyes JW , et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090-2096
Web of Science | Medline6
Steinert HC ,Hauser M ,Allemann F , et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441-446
Web of Science | Medline7
Vansteenkiste JF ,Stroobants SG ,De Leyn PR , et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-2149
Web of Science | Medline8
Bury T ,Barreto A ,Daenen F ,Barthelemy N ,Ghaye B ,Rigo P . Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-1247
CrossRef | Medline9
Weder W ,Schmid RA ,Bruchhaus H ,Hillinger S ,von Schulthess GK ,Steinert HC . Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-892
CrossRef | Web of Science | Medline10
Mountain CF . Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717
CrossRef | Web of Science | Medline11
Mountain CF ,Dresler CM . Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-1723
CrossRef | Web of Science | Medline12
Lonneux M ,Borbath I ,Bol A , et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med 1999;26:591-598
CrossRef | Medline13
Hamacher K ,Coenen HH ,Stocklin G . Efficient stereospecific synthesis of no-carrier-added 2-(18F)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238
Web of Science | Medline14
Medema J ,Luurtsema G ,Keizer H ,Tilkema SP ,Elsinga PH ,Vaalburg W . Performance of a fully automated and unattended production system of [18F]FDG. J Labelled Compd Radiopharm 1999;42:Suppl 1:S853-S85515
Brown RS ,Leung JY ,Kison PV ,Zasadny KR ,Flint A ,Wahl RL . Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999;40:556-565
Web of Science | Medline16
Valk PE ,Pounds TR ,Hopkins DM , et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-1581
CrossRef | Web of Science | Medline17
Imran MB ,Kubota K ,Yamada S , et al. Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images. J Nucl Med 1998;39:1219-1223
Web of Science | Medline18
Wahl RL ,Quint LE ,Greenough RL ,Meyer CR ,White RI ,Orringer MB . Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-377
Web of Science | Medline19
Vansteenkiste JF ,Stroobants SG ,Dupont PJ , et al. FGD-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? Eur J Nucl Med 1998;25:1495-1501
CrossRef | Medline20
Lewis PJ ,Salama A . Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-1649
Web of Science | Medline21
Kubota R ,Yamada S ,Kubota K ,Ishiwata K ,Tamahashi N ,Ido T . Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-1980
Web of Science | Medline22
Ahuja V ,Coleman RE ,Herndon J ,Patz EF Jr . The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-924
CrossRef | Web of Science | Medline23
Vansteenkiste JF ,Stroobants SG ,Dupont PJ , et al. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999;17:3201-3206
Web of Science | Medline
- Citing Articles (330)
Citing Articles
1
R. Cano Alonso, L. Herráiz Hidalgo, E. Álvarez Moreno, C. Paniagua Correa, V. Martínez de Vega. (2012) Papel de las técnicas de imagen en la nueva clasificación TNM del carcinoma broncogénico no microcítico. Radiología
CrossRef2
Jos A. Stigt, Ad H. Oostdijk, James E. Boers, Jan Willem K. van den Berg, Harry J.M. Groen. (2012) Percutaneous Ultrasound-Guided Biopsies in the Evaluation of Thoracic Tumours after PET-CT: A Prospective Diagnostic Study. Respiration 83:1, 45-52
CrossRef3
Hong Kyu Lee, Sung Woo Cho, Hee Sung Lee, Kun Il Kim, Hyoung Soo Kim, Seong Joon Cho. (2012) Comparing 18F-Fluorodeoxyglucose Positron Emission Tomography and Video-assisted Thoracoscopic Surgery in the Evaluation of Small Pulmonary Nodules in Patients with a History of Malignancy. The Korean Journal of Thoracic and Cardiovascular Surgery 45:1, 35
CrossRef4
Ching-Fei Chang, Afshin Rashtian, Michael K. Gould. (2011) The Use and Misuse of Positron Emission Tomography in Lung Cancer Evaluation. Clinics in Chest Medicine 32:4, 749-762
CrossRef5
Evangelia Skoura, Ioannis E. Datseris, Ioannis Platis, Georgios Oikonomopoulos, Konstantinos N. Syrigos. (2011) Role of Positron Emission Tomography in the Early Prediction of Response to Chemotherapy in Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef6
Guoping Chang, Tingting Chang, Tinsu Pan, John W. Clark, Osama R. Mawlawi. (2011) Determination of Internal Target Volume from a Single Positron Emission Tomography/Computed Tomography Scan in Lung Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef7
Francesco Fazi, Giulia Fontemaggi. (2011) MicroRNAs and Lymph Node Metastatic Disease in Lung Cancer. Thoracic Surgery Clinics
CrossRef8
S. E. Billmeier, J. Z. Ayanian, A. M. Zaslavsky, D. R. Nerenz, M. T. Jaklitsch, S. O. Rogers. (2011) Predictors and Outcomes of Limited Resection for Early-Stage Non-Small Cell Lung Cancer. JNCI Journal of the National Cancer Institute 103:21, 1621-1629
CrossRef9
Liucheng Wu, Yunfei Cao, Cun Liao, Jiahao Huang, Feng Gao. (2011) Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: A meta-analysis. European Journal of Radiology 80:2, 582-589
CrossRef10
Victoria Chernyak. (2011) Novel Imaging Modalities for Lymph Node Imaging in Urologic Oncology. Urologic Clinics of North America 38:4, 471-481
CrossRef11
Thomas B. Lanni, Inga S. Grills, Larry L. Kestin, John M. Robertson. (2011) Stereotactic Radiotherapy Reduces Treatment Cost While Improving Overall Survival and Local Control Over Standard Fractionated Radiation Therapy for Medically Inoperable Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology 34:5, 494-498
CrossRef12
Albert J. Chang, Farrokh Dehdashti, Jeffrey D. Bradley. (2011) The role of positron emission tomography for non-small cell lung cancer. Practical Radiation Oncology 1:4, 282-288
CrossRef13
S. Thureau, S. Mezzani-Saillard, R. Modzelewski, A. Edet-Sanson, B. Dubray, P. Vera. (2011) Intérêt de la TEP au FDG pour la radiothérapie des cancers bronchiques. Cancer/Radiothérapie 15:6-7, 504-508
CrossRef14
Kazuo Kubota, Koji Murakami, Tomio Inoue, Harumi Itoh, Tsuneo Saga, Susumu Shiomi, Jun Hatazawa. (2011) Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study. Annals of Nuclear Medicine
CrossRef15
John M. Varlotto, Abram Recht, John C. Flickinger, Laura N. Medford-Davis, Anne-Marie Dyer, Malcolm M. DeCamp. (2011) Lobectomy leads to optimal survival in early-stage small cell lung cancer: A retrospective analysis. The Journal of Thoracic and Cardiovascular Surgery 142:3, 538-546
CrossRef16
David P. Carbone, Enriqueta Felip. (2011) Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. Clinical Lung Cancer 12:5, 261-271
CrossRef17
Caecilia S. Reiner, Michael A. Fischer, Thomas Hany, Paul Stolzmann, Daniel Nanz, Olivio F. Donati, Dominik Weishaupt, Gustav K. von Schulthess, Hans Scheffel. (2011) Molecular Imaging of Malignant Tumor Metabolism. Academic Radiology 18:8, 940-946
CrossRef18
Reginald W. Dusing, Jeanne A. Drisko, Gordon G. Grado, Mark Levine, Jeffrey M. Holzbeierlein, Peter Van Veldhuizen. (2011) Prostate Imaging Modalities that Can Be Used for Complementary and Alternative Medicine Clinical Studies. Urologic Clinics of North America 38:3, 343-357
CrossRef19
Stephen Deppen, Joe B. Putnam, Gabriela Andrade, Theodore Speroff, Jonathan C. Nesbitt, Eric S. Lambright, Pierre P. Massion, Ron Walker, Eric L. Grogan. (2011) Accuracy of FDG-PET to Diagnose Lung Cancer in a Region of Endemic Granulomatous Disease. The Annals of Thoracic Surgery 92:2, 428-433
CrossRef20
Atsuya Takeda, Noriko Yokosuka, Toshio Ohashi, Etsuo Kunieda, Hirofumi Fujii, Yousuke Aoki, Naoko Sanuki, Naoyoshi Koike, Yukihiko Ozawa. (2011) The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiotherapy and Oncology
CrossRef21
Patricia Ibeas, Blanca Cantos, José Manuel Gasent, Begoña Rodríguez, Mariano Provencio. (2011) PET-CT in the staging and treatment of non-small-cell lung cancer. Clinical and Translational Oncology 13:6, 368-377
CrossRef22
Morihito Okada, Haruhiko Nakayama, Sakae Okumura, Hiromitsu Daisaki, Shuji Adachi, Masahiro Yoshimura, Yoshihiro Miyata. (2011) Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. The Journal of Thoracic and Cardiovascular Surgery 141:6, 1384-1391
CrossRef23
Zhongxing Liang, Heidi T. Cho, Larry Williams, Aizhi Zhu, Ke Liang, Ke Huang, Hui Wu, Chunsu Jiang, Samuel Hong, Ronald Crowe, Mark M. Goodman, Hyunsuk Shim. (2011) Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression. Nuclear Medicine and Molecular Imaging 45:2, 93-102
CrossRef24
Shirish M. Gadgeel, John C. Ruckdeschel, Bhaumik B. Patel, Antoinette Wozniak, Andre Konski, Manuel Valdivieso, Deborah Hackstock, Wei Chen, Kimberly Belzer, Angelika M. Burger, Lauren Marquette, Andrew Turrisi. (2011) Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:5, 927-933
CrossRef25
Andreas K. Buck, Ken Herrmann, Jonas Schreyögg. (2011) PET/CT for staging lung cancer: costly or cost-saving?. European Journal of Nuclear Medicine and Molecular Imaging 38:5, 799-801
CrossRef26
Gregory J. Kubicek, Dwight E. Heron. (2011) Clinical Applications of PET-Computed Tomography in Planning Radiotherapy: General Principles and an Overview. PET Clinics 6:2, 105-115
CrossRef27
Xinhua Qu, Xiaolu Huang, Weili Yan, Lianming Wu, Kerong Dai. (2011) A meta-analysis of 18FDG-PET–CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. European Journal of Radiology
CrossRef28
Mert Saynak, Nirmal K. Veeramachaneni, Jessica L. Hubbs, Jiho Nam, Bahjat F. Qaqish, Janet E. Bailey, Wonil Chung, Lawrence B. Marks. (2011) Local failure after complete resection of N0–1 non-small cell lung cancer. Lung Cancer 71:2, 156-165
CrossRef29
Jouke T. Annema, Klaus F. Rabe. 2011. EUS and EBUS in Non–Small Cell Lung Cancer. , 45-58.
CrossRef30
Erdogan Cetinkaya, Ekrem Cengiz Seyhan, Akif Ozgul, Atayla Gencoglu, Guler Ozgul, Ertan Cam, Emine Kamiloglu. (2011) Efficacy of Convex Probe Endobronchial Ultrasound (CP-EBUS) Assisted Transbronchial Needle Aspiration for Mediastinal Staging in Non-small Cell Lung Cancer Cases with Mediastinal Lymphadenopathy. Annals of Thoracic and Cardiovascular Surgery 17:3, 236-242
CrossRef31
Yohei Imamura, Koichi Azuma, Seiji Kurata, Satoshi Hattori, Tetsuro Sasada, Takashi Kinoshita, Masaki Okamoto, Tomotaka Kawayama, Hayato Kaida, Masatoshi Ishibashi, Hisamichi Aizawa. (2011) Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer 71:1, 49-54
CrossRef32
Jeong Won Lee, Seok-Ki Kim, Ji Won Park, Hyun-Sung Lee. (2010) Unexpected Small Bowel Intussusception Caused by Lung Cancer Metastasis on 18F-Fluorodeoxyglucose PET-CT. The Annals of Thoracic Surgery 90:6, 2037-2039
CrossRef33
Sebastian A. Defranchi, Eric S. Edell, Craig E. Daniels, Udaya B.S. Prakash, Karen L. Swanson, James P. Utz, Mark S. Allen, Stephen D. Cassivi, Claude Deschamps, Francis C. Nichols, K. Robert Shen, Dennis A. Wigle. (2010) Mediastinoscopy in Patients With Lung Cancer and Negative Endobronchial Ultrasound Guided Needle Aspiration. The Annals of Thoracic Surgery 90:6, 1753-1757
CrossRef34
Sarah Everitt, Alan Herschtal, Jason Callahan, Nikki Plumridge, David Ball, Tomas Kron, Michal Schneider-Kolsky, David Binns, Rodney J. Hicks, Michael MacManus. (2010) High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer 116:21, 5030-5037
CrossRef35
Eun Young HEO, Seock-Chul YANG, Chul-Gyu YOO, Sung Koo HAN, Young-Soo SHIM, Young Whan KIM. (2010) Impact of whole-body 18F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer. Respirology 15:8, 1174-1178
CrossRef36
Daniel P. Steinfort, Danny Liew, Matthew Conron, Anastasia F. Hutchinson, Louis B. Irving. (2010) Cost-Benefit of Minimally Invasive Staging of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1564-1570
CrossRef37
J. Vansteenkiste, C. Dooms, P. De Leyn. (2010) Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment: evidence-based staging. Annals of Oncology 21:Supplement 7, vii189-vii195
CrossRef38
Kazuhiro Yasufuku, Shaf Keshavjee. (2010) Staging Non–Small Cell Lung Cancer. Clinical Pulmonary Medicine 17:5, 223-231
CrossRef39
Albert J. Chang, Jeffrey D. Bradley. (2010) Clinical Perspectives on Dose Escalation for Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:5, 299-302
CrossRef40
Mei L. Yap, S.K. Vinod, I.A. Ho Shon, A. Fowler, M. Lin, G. Gabriel, L.C. Holloway. (2010) The Registration of Diagnostic versus Planning Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Radiotherapy Planning for Non-small Cell Lung Cancer. Clinical Oncology 22:7, 554-560
CrossRef41
Saiyada N.F. Rizvi, Emile F. Comans, Ronald Boellaard, Harm van Tinteren, Otto S. Hoekstra. (2010) Two decades at the cross-roads of biology, physics and epidemiology: Lessons learned in [18F-]FDG positron emission tomography in oncology. European Journal of Cancer 46:12, 2150-2158
CrossRef42
L.- R. He, H.- Y. Zhao, B.- K. Li, L.- J. Zhang, M.- Z. Liu, H.- F. Kung, X.- Y. Guan, X.- W. Bian, Y.- X. Zeng, D. Xie. (2010) Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Annals of Oncology 21:8, 1675-1681
CrossRef43
Hyeon Tae Jeong, Mijin Yun, Hye-Suk Hong, Jong Doo Lee, Ki Whang Kim. (2010) Unusual Gallbladder Metastasis From Non–Small-Cell Lung Cancer Detected by F-18 FDG PET/CT With Intravenous Contrast Enhancement. Clinical Nuclear Medicine 35:8, 635-636
CrossRef44
Kazuhiro Yasufuku. (2010) Current clinical applications of endobronchial ultrasound. Expert Review of Respiratory Medicine 4:4, 491-498
CrossRef45
Haruhiko Nakayama, Sakae Okumura, Hiromitsu Daisaki, Yasufumi Kato, Hirofumi Uehara, Shuji Adachi, Masahiro Yoshimura, Morihito Okada. (2010) Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma. Cancer 116:13, 3170-3177
CrossRef46
B.C. John Cho, Andrea Bezjak, Laura A. Dawson. (2010) Image Guidance in Non–Small Cell Lung Cancer. Seminars in Radiation Oncology 20:3, 164-170
CrossRef47
Wei Chen, Wang Jian, Hai-tao Li, Chuan Li, Yong-ke Zhang, Bin Xie, Dai-quan Zhou, Yong-ming Dai, Yun Lin, Ming Lu, Xue-quan Huang, Chun-xia Xu, Lin Chen. (2010) Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?. Magnetic Resonance Imaging 28:5, 613-620
CrossRef48
Rodrigo Alonso Moralejo, Javier Sayas Catalán, Ricardo García Luján, Mónica Coronado Poggio, Eduard Monsó Molas, Ángel López Encuentra. (2010) Utilidad de la tomografía por emisión de positrones en la detección de metástasis ocultas extratorácicas en el carcinoma broncogénico no células pequeñas. Archivos de Bronconeumología 46:5, 238-243
CrossRef49
Hiromitsu Daisaki, Hiroyuki Shinohara, Takashi Terauchi, Takeshi Murano, Naoki Shimada, Noriyuki Moriyama, Ukihide Tateishi. (2010) Multi-bed-position acquisition technique for deep inspiration breath-hold PET/CT: a preliminary result for pulmonary lesions. Annals of Nuclear Medicine 24:3, 179-188
CrossRef50
Mohit Agarwal, Govinda Brahmanday, Sunil K. Bajaj, K. P. Ravikrishnan, Ching-Yee Oliver Wong. (2010) Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). European Journal of Nuclear Medicine and Molecular Imaging 37:4, 691-698
CrossRef51
Firuz Celikoglu, Seyhan I. Celikoglu, Eugene P. Goldberg. (2010) Intratumoural chemotherapy of lung cancer for diagnosis and treatment of draining lymph node metastasis. Journal of Pharmacy and Pharmacology 62:3, 287-295
CrossRef52
Hee Suk Jung, Yong Hee Kim, Seung-Il Park, Dong-Kwan Kim. (2010) The Safety and Usefulness of Combined Video-Assisted Mediastinoscopic Lymph Adenectomy and Video-Assisted Thoracic Surgery Lobectomy for Left-sided Lung Cancer. The Korean Journal of Thoracic and Cardiovascular Surgery 43:1, 33
CrossRef53
Daniel Morgensztern, Shean Huey Ng, Feng Gao, Ramaswamy Govindan. (2010) Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:1, 29-33
CrossRef54
Ji-Hoon Kim, Won Sang Chung, Young-Hak Kim, Hyuck Kim, Seok-Chol Jeon. (2010) Accuracy of Nodal Staging with Integrated PET/CT Scanning in Non-small Cell Lung Cancer. The Korean Journal of Thoracic and Cardiovascular Surgery 43:6, 700
CrossRef55
Edith M. Marom. 2010. Imaging Tumors of the Lung and Pleura. , 1-40.
CrossRef56
Vijay K. Nuthakki, Ali Mahtabifard, Robert J. McKenna. 2010. Mediastinoscopy and Mediastinotomy. , 72-77.
CrossRef57
Alan Waxman, Yoko Ozawa. 2010. Nuclear Medicine Imaging in Thoracic Surgery. , 30-59.
CrossRef58
S. Melanie Greaves, Kathleen Brown. 2010. Imaging of the Thoracic Surgery Patient. , 1-29.
CrossRef59
M. Lin, I. Ho Shon, P. Lin. (2010) Positron emission tomography: current status and future challenges. Internal Medicine Journal 40:1, 19-29
CrossRef60
Ho Yun Lee, Joungho Han, Kyung Soo Lee, Ji Hyun Koo, Sun Young Jeong, Byung-Tae Kim, Young-Seok Cho, Young Mog Shim, Jhingook Kim, Kwanmien Kim, Yong Soo Choi. (2009) Lung adenocarcinoma as a solitary pulmonary nodule: Prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer 66:3, 379-385
CrossRef61
Mizue Hasegawa, Fumikazu Sakai, Fumiko Kimura, Kaiji Inoue, Atsushi Nagai. (2009) Size of noncancerous hilomediastinal lymph nodes measured on coronal and sagittal reconstruction CT images. Japanese Journal of Radiology 27:10, 416-422
CrossRef62
Ayesha S. Bryant, Robert J. Cerfolio. (2009) Diagnosis, staging and treatment of patients with non-small cell lung cancer for the surgeon. Indian Journal of Surgery 71:6, 310-316
CrossRef63
S Vauclin, K Doyeux, S Hapdey, A Edet-Sanson, P Vera, I Gardin. (2009) Development of a generic thresholding algorithm for the delineation of 18 FDG-PET-positive tissue: application to the comparison of three thresholding models. Physics in Medicine and Biology 54:22, 6901-6916
CrossRef64
Jeong Won Lee, Bom Sahn Kim, Dong Soo Lee, June-Key Chung, Myung Chul Lee, Soonhag Kim, Won Jun Kang. (2009) 18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity. European Journal of Nuclear Medicine and Molecular Imaging 36:11, 1794-1802
CrossRef65
Mark Levine, Jim Julian. (2009) Imaging: PET–CT imaging in non-small-cell lung cancer. Nature Reviews Clinical Oncology 6:11, 619-620
CrossRef66
Wim J. G. Oyen, Winette T. A. van der Graaf. (2009) Molecular imaging of solid tumors: exploiting the potential. Nature Reviews Clinical Oncology 6:10, 609-611
CrossRef67
Jin Woo Song, Yeon-Mock Oh, Tae-Sun Shim, Woo Sung Kim, Jin-Sook Ryu, Chang-Min Choi. (2009) Efficacy comparison between 18F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 65:3, 333-338
CrossRef68
Sebastian A. Defranchi, Stephen D. Cassivi, Francis C. Nichols, Mark S. Allen, K. Robert Shen, Claude Deschamps, Dennis A. Wigle. (2009) N2 Disease in T1 Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 88:3, 924-928
CrossRef69
Johan Vansteenkiste, Christophe Dooms, Paul De Leyn. (2009) The multidisciplinarity of stage III non-small cell lung cancer. European Journal of Cancer 45, 92-105
CrossRef70
Gerwin P. Schmidt, Maximilian F. Reiser, Andrea Baur-Melnyk. (2009) Whole-body MRI for the staging and follow-up of patients with metastasis. European Journal of Radiology 70:3, 393-400
CrossRef71
A.E. Dassen, D.J. Lips, C.J. Hoekstra, J.F.M. Pruijt, K. Bosscha. (2009) FDG-PET has no definite role in preoperative imaging in gastric cancer. European Journal of Surgical Oncology (EJSO) 35:5, 449-455
CrossRef72
I. Pinilla, N. Gómez León. (2009) Utilidad de la PET/TC en el cáncer de pulmón. Radiología 51:3, 248-260
CrossRef73
Yasumitsu Moriya, Akira Iyoda, Yasuhiro Kasai, Takashi Sugimoto, Junya Hashida, Yoshinori Nimura, Masaki Kato, Masaki Takiguchi, Takehiko Fujisawa, Naohiko Seki, Ichiro Yoshino. (2009) Prediction of lymph node metastasis by gene expression profiling in patients with primary resected lung cancer. Lung Cancer 64:1, 86-91
CrossRef74
Kyoichi Kaira, Noboru Oriuchi, Kimihiro Shimizu, Tomohiro Ishikita, Tetsuya Higuchi, Hisao Imai, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Keigo Endo, Masatomo Mori. (2009) Correlation of angiogenesis with 18 F-FMT and 18 F-FDG uptake in non-small cell lung cancer. Cancer Science 100:4, 753-758
CrossRef75
Farhood Farjah, David R. Flum, Thomas K. Varghese, Rebecca Gaston Symons, Douglas E. Wood. (2009) Surgeon Specialty and Long-Term Survival After Pulmonary Resection for Lung Cancer. The Annals of Thoracic Surgery 87:4, 995-1006
CrossRef76
Nai-Ming Cheng, Chih-Teng Yu, Kung-Chu Ho, Yi-Cheng Wu, Yuan-Chang Liu, Chih-Wei Wang, Tzu-Chen Yen. (2009) Respiration-averaged CT for attenuation correction in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 36:4, 607-615
CrossRef77
Melvin Lee Kiang Chua, Seng Chuan Ong, Joseph Tien Seng Wee, David Chee Eng Ng, Fei Gao, Terence Wee Kiat Tan, Kam Weng Fong, Eu Tiong Chua, James Boon Kheng Khoo, John Seng Hooi Low. (2009) Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head & Neck 31:3, 346-354
CrossRef78
Kyoichi Kaira, Noboru Oriuchi, Kimihiro Shimizu, Tomohiro Ishikita, Tetsuya Higuchi, Hisao Imai, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Keigo Endo, Masatomo Mori. (2009) Evaluation of thoracic tumors with 18 F-FMT and 18 F-FDG PET-CT: A clinicopathological study. International Journal of Cancer 124:5, 1152-1160
CrossRef79
Farhood Farjah, David R. Flum, Scott D. Ramsey, Patrick J. Heagerty, Rebecca Gaston Symons, Douglas E. Wood. (2009) Multi-Modality Mediastinal Staging for Lung Cancer Among Medicare Beneficiaries. Journal of Thoracic Oncology 4:3, 355-363
CrossRef80
S. A. Nehmeh, H. El-Zeftawy, C. Greco, J. Schwartz, Y. E. Erdi, A. Kirov, C. R. Schmidtlein, A. B. Gyau, S. M. Larson, J. L. Humm. (2009) An iterative technique to segment PET lesions using a Monte Carlo based mathematical model. Medical Physics 36:10, 4803
CrossRef81
Sameer K. Nath, Daniel R. Simpson, Brent S. Rose, Ajay P. Sandhu. (2009) Recent Advances in Image-Guided Radiotherapy for Head and Neck Carcinoma. Journal of Oncology 2009, 1-10
CrossRef82
Hee Yun Seol, Jeong Ha Mok, Seong Hoon Yoon, Ji Eun Kim, Ki Uk Kim, Hye-Kyung Park, Seong Jang Kim, Yun Seong Kim, Min Ki Lee, Soon Kew Park. (2009) Association between Bone Marrow Hypermetabolism on 18 F-Fluorodeoxyglucose Positron Emission Tomography and Response to Chemotherapy in Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases 66:1, 20
CrossRef83
Kazuhiro Imai, Yoshihiro Minamiya, Hajime Saito, Taku Nakagawa, Yukiko Hosono, Hiroshi Nanjo, Kasumi Tozawa, Masaji Hashimoto, Yoshihiko Kimura, Jun-Ichi Ogawa. (2008) Accuracy of helical computed tomography for the identification of lymph node metastasis in resectable non-small cell lung cancer. Surgery Today 38:12, 1083-1090
CrossRef84
Sandra Pauls, Felix M. Mottaghy, Stefan A. Schmidt, Stefan Krüger, Peter Möller, Hans-Jürgen Brambs, Arthur Wunderlich. (2008) Evaluation of lung tumor perfusion by dynamic contrast-enhanced MRI. Magnetic Resonance Imaging 26:10, 1334-1341
CrossRef85
N A Shkumat, J H Siewerdsen, A C Dhanantwari, D B Williams, N S Paul, J Yorkston, R Van Metter. (2008) Cardiac gating with a pulse oximeter for dual-energy imaging. Physics in Medicine and Biology 53:21, 6097-6112
CrossRef86
Shawn S. Groth, Bryan A. Whitson, Michael A. Maddaus. (2008) Radiographic Staging of Mediastinal Lymph Nodes in Non–Small Cell Lung Cancer Patients. Thoracic Surgery Clinics 18:4, 349-361
CrossRef87
Rachel E. Sanborn, Brian E. Lally. (2008) Adjuvant Therapy for Non–Small Cell Lung Cancer with Mediastinal Nodal Involvement. Thoracic Surgery Clinics 18:4, 423-435
CrossRef88
Dwight E. Heron, Regiane S. Andrade, Sushil Beriwal, Ryan P. Smith. (2008) PET-CT in Radiation Oncology. American Journal of Clinical Oncology 31:4, 352-362
CrossRef89
Sang-June Park, Dan Ionascu, Joseph Killoran, Marcelo Mamede, Victor H Gerbaudo, Lee Chin, Ross Berbeco. (2008) Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images. Physics in Medicine and Biology 53:13, 3661-3679
CrossRef90
Wenfeng Yang, Zheng Fu, Jinming Yu, Shuanghu Yuan, Baijiang Zhang, Daotang Li, Ligang Xing, Dongbo Zhao, Dianbin Mu, Xiaorong Sun, Yufang Fang, Yong Huange, Wanhu Li. (2008) Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer 61:1, 35-43
CrossRef91
Ruoh-Fang Yen, Ke-Cheng Chen, Jang-Ming Lee, Yeun-Chung Chang, Jane Wang, Mei-Fang Cheng, Yen-Wen Wu, Yung-Chie Lee. (2008) 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort?. European Journal of Nuclear Medicine and Molecular Imaging 35:7, 1305-1315
CrossRef92
Sharyn Katz, Thomas Ferrara, Abass Alavi, Drew A. Torigian. (2008) PET, CT, and MR Imaging for Assessment of Thoracic Malignancy: Structure Meets Function. PET Clinics 3:3, 395-410
CrossRef93
Kazuhiro Yasufuku, Takahiro Nakajima, Taiki Fujiwara, Masako Chiyo, Akira Iyoda, Shigetoshi Yoshida, Makoto Suzuki, Yasuo Sekine, Kiyoshi Shibuya, Ichiro Yoshino. (2008) Role of endobronchial ultrasound-guided transbronchial needle aspiration in the management of lung cancer. General Thoracic and Cardiovascular Surgery 56:6, 268-276
CrossRef94
Ho-Young Lee, June-Key Chung, Jae Min Jeong, Dong Soo Lee, Dong Gyu Kim, Hee Won Jung, Myung Chul Lee. (2008) Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Annals of Nuclear Medicine 22:4, 281-286
CrossRef95
Christian Plathow, Philip Aschoff, Mathias Philip Lichy, Susanne Eschmann, Thomas Hehr, Ingo Brink, Claus D. Claussen, Christina Pfannenberg, Heinz-Peter Schlemmer. (2008) Positron Emission Tomography/Computed Tomography and Whole-Body Magnetic Resonance Imaging in Staging of Advanced Nonsmall Cell Lung Cancer???Initial Results. Investigative Radiology 43:5, 290-297
CrossRef96
S. Hughes, J. McClelland, A. Chandler, M. Adams, J. Boutland, D. Withers, S. Ahmad, J. Blackall, S. Tarte, D. Hawkes, D. Landau. (2008) A Comparison of Internal Target Volume Definition by Limited Four-dimensional Computed Tomography, the Addition of Patient-specific Margins, or the Addition of Generic Margins when Planning Radical Radiotherapy for Lymph Node-positive Non-small Cell Lung Cancer. Clinical Oncology 20:4, 293-300
CrossRef97
Julian R. Molina, Ping Yang, Stephen D. Cassivi, Steven E. Schild, Alex A. Adjei. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings 83:5, 584-594
CrossRef98
J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, A. A. Adjei. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings 83:5, 584-594
CrossRef99
C. Plathow, M. Walz, M.P. Lichy, P. Aschoff, C. Pfannenberg, H. Bock, S.M. Eschmann, C.D. Claussen, H.P. Schlemmer. (2008) Kostenüberlegungen zur Ganzkörper-MRT und PET-CT im Rahmen des onkologischen Stagings. Der Radiologe 48:4, 384-396
CrossRef100
Benjamin D. Kozower, Bryan F. Meyers, Carolyn E. Reed, David R. Jones, Paul A. Decker, Joe B. Putnam. (2008) Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer?. The Annals of Thoracic Surgery 85:4, 1166-1170
CrossRef101
Sandra Pauls, Andreas K. Buck, Gisela Halter, Felix M. Mottaghy, Rainer Muche, Christina Bluemel, Susanne Gerstner, Stefan Krüger, Gerhard Glatting, Ludger Sunder-Plassmann, Peter Möller, Hans-Jürgen Brambs, Sven N. Reske. (2008) Performance of Integrated FDG-PET/CT for Differentiating Benign and Malignant Lung Lesions -Results from a Large Prospective Clinical Trial. Molecular Imaging and Biology 10:2, 121-128
CrossRef102
Jeremy J. Erasmus, Bradley S. Sabloff. (2008) CT, Positron Emission Tomography, and MRI in Staging Lung Cancer. Clinics in Chest Medicine 29:1, 39-57
CrossRef103
Homer A. Macapinlac. (2008) Clinical Applications of Positron Emission Tomography/Computed Tomography Treatment Planning. Seminars in Nuclear Medicine 38:2, 137-140
CrossRef104
Tomohide Sugiyama, Takashi Hirose, Takamichi Hosaka, Sojiro Kusumoto, Masanao Nakashima, Toshimitsu Yamaoka, Kentaro Okuda, Tohru Ohmori, Mitsuru Adachi. (2008) Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung Cancer 59:2, 255-261
CrossRef105
N. J. Dickgreber, S. Fischer, T. Welte. (2008) Präoperatives Staging bei Patienten mit nichtkleinzelligem Bronchialkarzinom. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 22:1, 56-62
CrossRef106
Boone Goodgame, Giancarlo A. Pillot, Zhiyun Yang, Jabi Shriki, Bryan F. Meyers, Jennifer Zoole, Feng Gao, Farrokh Dehdashti, Alexander Patterson, Barry A. Siegel, Ramaswamy Govindan. (2008) Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:2, 130-134
CrossRef107
Daniel Morgensztern, Boone Goodgame, Maria Q. Baggstrom, Feng Gao, Ramaswamy Govindan. (2008) The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:2, 135-139
CrossRef108
Joe Y. Chang, Lei Dong, Helen Liu, George Starkschall, Peter Balter, Radhe Mohan, Zhongxing Liao, James D. Cox, Ritsuko Komaki. (2008) Image???Guided Radiation Therapy for Non???small Cell Lung Cancer. Journal of Thoracic Oncology 3:2, 177-186
CrossRef109
F HAMPSON. (2008) Response assessment in lymphoma. Clinical Radiology 63:2, 125-135
CrossRef110
Adam S. Feldman, W. Scott McDougal, Mukesh G. Harisinghani. (2008) The potential of nanoparticle-enhanced imaging. Urologic Oncology: Seminars and Original Investigations 26:1, 65-73
CrossRef111
Peter W. A. Kunst, Ralph Eberhardt, Felix J. F. Herth. (2008) Combined EBUS Real Time TBNA and Conventional TBNA are the Most Cost-effective Means of Lymph Node Staging. Journal of Bronchology 15:1, 17-20
CrossRef112
Steven E. Weinberger, Barbara A. Cockrill, Jess Mandel. 2008. Lung Cancer: Clinical Aspects. , 263-275.
CrossRef113
Stephen G. Spiro, John Buscombe, Gary Cook, Tim Eisen, Fergus Gleeson, Mary O’Brien, Michael D. Peake, Nicholas P. Rowell, Richard Seymour. (2008) Ensuring the right PET scan for the right patient. Lung Cancer 59:1, 48-56
CrossRef114
E. Günter. (2008) Transösophagealer Ultraschall zur Diagnostik im Mediastinum. Der Chirurg 79:1, 56-60
CrossRef115
Agata Rembielak, Pat Price. (2008) The Role of PET in Target Localization for Radiotherapy Treatment Planning. Onkologie 31:1-2, 57-62
CrossRef116
Tatsuo Kimura, Koichi Koyama, Shinzoh Kudoh, Joji Kawabe, Naruo Yoshimura, Shigeki Mitsuoka, Susumu Shiomi, Kazuto Hirata. (2008) Monitoring of Chemotherapy Response in Malignant Pleural Mesothelioma Using Fluorodeoxyglucose Positron Emission Tomography. Internal Medicine 47:23, 2053-2056
CrossRef117
António Bugalho, Michael K. Doris, Juerg Hamacher, Ralf Eberhardt, Felix J. Herth. (2008) Ecoendoscopia brônquica: Aspectos práticos e aplicabilidade clínica. Revista Portuguesa de Pneumologia (English Edition) 14:1, 55-88
CrossRef118
K LEE. 2008. Lung Cancer StagingIntegrated 18F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography and Computed Tomography Alone. , 171-176.
CrossRef119
H VANTINTEREN. 2008. Evaluating Positron Emission Tomography in Non-small cell Lung CancerMoving Beyond Accuracy to Outcome. , 249-256.
CrossRef120
G. Giaccone. (2007) 18Fluorodeoxyglucose Positron Emission Tomography, a Standard Diagnostic Tool in Lung Cancer. JNCI Journal of the National Cancer Institute 99:23, 1741-1743
CrossRef121
Y. C. Ung, D. E. Maziak, J. A. Vanderveen, C. A. Smith, K. Gulenchyn, C. Lacchetti, W. K. Evans, . (2007) 18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review. JNCI Journal of the National Cancer Institute 99:23, 1753-1767
CrossRef122
I. Borrego Dorado, C. López García, R. Vázquez Albertino, A. Ginel Cañamaque, E. Barrot Cortés. (2007) Evaluación de la eficacia y el impacto clínico de la PET-FDG en los pacientes con carcinoma broncopulmonar no microcítico candidatos a cirugía. Revista Española de Medicina Nuclear 26:6, 335-344
CrossRef123
Mai Russell, Yoshimi Anzai. (2007) Ultrasmall superparamagnetic iron oxide enhanced MR imaging for lymph node metastases. Radiography 13, e73-e84
CrossRef124
A. Rodríguez Fernández, M.E. Bellón Guardia, M. Gómez Río, C. Ramos Font, A. Sánchez-Palencia Ramos, J.M. Llamas Elvira, V. Pedraza Muriel. (2007) Estadificación del cáncer de pulmón de células no pequeñas. Utilidad de la imagen estructural (TAC) y funcional (FDG-PET). Revista Clínica Española 207:11, 541-547
CrossRef125
Ann Hoge Klopp, Joe Y. Chang, Susan L. Tucker, Erik P. Sulman, Peter A. Balter, H. Helen Liu, M. Kara Bucci, Homer A. Macapinlac, Ritsuko Komaki, James D. Cox. (2007) Intrathoracic Patterns of Failure for Non–Small-Cell Lung Cancer With Positron-Emission Tomography/Computed Tomography–Defined Target Delineation. International Journal of Radiation Oncology*Biology*Physics 69:5, 1409-1416
CrossRef126
Jeremy J. Erasmus, Homer A. Macapinlac, Stephen G. Swisher. (2007) Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer 110:10, 2155-2168
CrossRef127
Ali A Siddiqui, Mohamad A Eloubeidi. (2007) Esophageal endoscopic ultrasound fine-needle aspiration as a diagnostic tool. Expert Opinion on Medical Diagnostics 1:3, 423-431
CrossRef128
Wouter K. de Jong, Henricus F.M. van der Heijden, Jan Pruim, Otilia Dalesio, Wim J.G. Oyen, Harry J.M. Groen. (2007) Prognostic Value of Different Metabolic Measurements with Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Resectable Non-Small Cell Lung Cancer: A Two-Center Study. Journal of Thoracic Oncology 2:11, 1007-1012
CrossRef129
Lioe-Fee de Geus-Oei, Henricus F.M. van der Heijden, Frans H.M. Corstens, Wim J.G. Oyen. (2007) Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer. Cancer 110:8, 1654-1664
CrossRef130
Peter W. A. Kunst, Pyng Lee, Marinus A. Paul, Suresh Senan, Egbert F. Smit. (2007) Restaging of Mediastinal Nodes with Transbronchial Needle Aspiration after Induction Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:10, 912-915
CrossRef131
F. Vaylet, F. Rivière, H. Le Floch, A. Bonnichon, A. Mairovitz, E. Staub, G. Bonardel, J. Margery, M. Mantzarides, C. Marotel, H. Foehrenbach. (2007) 18F-FDG-TEP : sa place dans le diagnostic et la surveillance du cancer bronchique non à petites cellules. Revue des Maladies Respiratoires 24:8, 35-39
CrossRef132
Antonio Maldonado, Francisco Javier González-Alenda, Mercedes Alonso, José María Sierra. (2007) Utilidad de la tomografía por emisión de positrones-tomografía computarizada (PET-TC) en neumología. Archivos de Bronconeumología 43:10, 562-572
CrossRef133
Kazuhiro Yasufuku, Takahiro Nakajima, Masako Chiyo, Yasuo Sekine, Kiyoshi Shibuya, Takehiko Fujisawa. (2007) Endobronchial Ultrasonography: Current Status and Future Directions. Journal of Thoracic Oncology 2:10, 970-979
CrossRef134
Timothy M. Pawlik, Ana Luiza Gleisner, Todd W. Bauer, Reid B. Adams, Srinevas K. Reddy, Bryan M. Clary, Robert C. Martin, Charles R. Scoggins, Kenneth K. Tanabe, James S. Michaelson, David A. Kooby, Charles A. Staley, Richard D. Schulick, Jean-Nicolas Vauthey, Eddie K. Abdalla, Steven A Curley, Michael A Choti, Dominque Elias. (2007) Liver-Directed Surgery for Metastatic Squamous Cell Carcinoma to the Liver: Results of a Multi-Center Analysis. Annals of Surgical Oncology 14:10, 2807-2816
CrossRef135
Robert James Cerfolio, Ayesha S. Bryant. (2007) The Role of Integrated Positron Emission Tomography-Computerized Tomography in Evaluating and Staging Patients with Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 19:3, 192-200
CrossRef136
Yoshiharu Ohno, Hisanobu Koyama, Munenobu Nogami, Daisuke Takenaka, Takeshi Yoshikawa, Masahiro Yoshimura, Yoshikazu Kotani, Yoshihiro Nishimura, Takanori Higashino, Kazuro Sugimura. (2007) Whole-body MR imaging vs. FDG-PET: Comparison of accuracy of M-stage diagnosis for lung cancer patients. Journal of Magnetic Resonance Imaging 26:3, 498-509
CrossRef137
Nobukazu Fuwa, Tetsuya Mitsudomi, Takashi Daimon, Yasushi Yatabe, Masahiro Shinoda, Shunzou Hatooka, Schuichi Mori, Takayuki Fukui, Yoshitaka Inaba. (2007) Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer—From studies of 604 surgical cases. Lung Cancer 57:3, 311-316
CrossRef138
Jong-Lyel Roh, Chang Hwan Ryu, Jae Seung Kim, Jin Seong Lee, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim. (2007) Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer. Oral Oncology 43:8, 757-763
CrossRef139
E. Festic, P. J. Abraham, O. L. Burnett, P. M. Young, M. M. Johnson. (2007) Increased Radiotracer Uptake on Positron Emission Tomography After Invasive Thoracic Procedures: A Case Series. Mayo Clinic Proceedings 82:9, 1060-1064
CrossRef140
Jeffrey L. Port, Paul C. Lee, Robert J. Korst, Yaakov Liss, Danish Meherally, Paul Christos, Madhu Mazumdar, Nasser K. Altorki. (2007) Positron Emission Tomographic Scanning Predicts Survival After Induction Chemotherapy for Esophageal Carcinoma. The Annals of Thoracic Surgery 84:2, 393-400
CrossRef141
Cuneyt Turkmen, Kerim Sonmezoglu, Alper Toker, Dilek Ylmazbayhan, Sukru Dilege, Metin Halac, Mustafa Erelel, Turhan Ece, Ayse Mudun. (2007) The Additional Value of FDG PET Imaging for Distinguishing N0 or N1 From N2 Stage in Preoperative Staging of Non-small Cell Lung Cancer in Region Where the Prevalence of Inflammatory Lung Disease Is High. Clinical Nuclear Medicine 32:8, 607-612
CrossRef142
Jokke Wynants, Sigrid Stroobants, Christophe Dooms, Johan Vansteenkiste. (2007) Staging of Lung Cancer. Radiologic Clinics of North America 45:4, 609-625
CrossRef143
Pyng Lee, Henri G. Colt. (2007) State of the Art: Pleuroscopy. Journal of Thoracic Oncology 2:7, 663-670
CrossRef144
Lawrence Shulman, David Ost. (2007) Advances in bronchoscopic diagnosis of lung cancer. Current Opinion in Pulmonary Medicine 13:4, 271-277
CrossRef145
Gerwin P. Schmidt, Harald Kramer, Maximilian F. Reiser, Christian Glaser. (2007) Whole-Body Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography in Oncology. Topics in Magnetic Resonance Imaging 18:3, 193-202
CrossRef146
Morihito Okada, Shunsuke Tauchi, Koichiro Iwanaga, Takeshi Mimura, Yoshitaka Kitamura, Hirokazu Watanabe, Shuji Adachi, Toshiko Sakuma, Chiho Ohbayashi. (2007) Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas. The Journal of Thoracic and Cardiovascular Surgery 133:6, 1448-1454
CrossRef147
S. T. Lee, S. U. Berlangieri, A. M. T. Poon, P. Mitchell, K. Pathmaraj, K. Tabone, A. J. Byrne, G. J. O?Keefe, S. R. Knight, C. P. Clarke, A. M. Scott. (2007) Prevalence of occult metastatic disease in patients undergoing 18 F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. Internal Medicine Journal 0:0, 070521010100001-???
CrossRef148
G. Mangili, M. Picchio, S. Sironi, R. Viganò, E. Rabaiotti, D. Bornaghi, V. Bettinardi, C. Crivellaro, C. Messa, F. Fazio. (2007) Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging 34:5, 658-666
CrossRef149
Susanne Martina Eschmann, Godehard Friedel, Frank Paulsen, Matthias Reimold, Thomas Hehr, Wilfried Budach, Heinz-Jakob Langen, Roland Bares. (2007) 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 34:4, 463-471
CrossRef150
Inga S. Grills, Di Yan, Quinten C. Black, Ching-Yee O. Wong, Alvaro A. Martinez, Larry L. Kestin. (2007) Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non–small-cell lung cancer. International Journal of Radiation Oncology*Biology*Physics 67:3, 709-719
CrossRef151
Johan Vansteenkiste, Christophe Dooms. (2007) Positron emission tomography in nonsmall cell lung cancer. Current Opinion in Oncology 19:2, 78-83
CrossRef152
Y. Pallardó Calatayud, A.J. Revert Ventura, E. Castañer González. (2007) Actualización en la estadificación del cáncer de pulmón. Radiología 49:2, 83-96
CrossRef153
Kazuhiro YASUFUKU, Takehiko FUJISAWA. (2007) Staging and diagnosis of non-small cell lung cancer: Invasive modalities. Respirology 12:2, 173-183
CrossRef154
Victoria Kut, William Spies, Stewart Spies, William Gooding, Athanassios Argiris. (2007) Staging and Monitoring of Small Cell Lung Cancer Using [18F]Fluoro-2-deoxy-D-glucose-Positron Emission Tomography (FDG-PET). American Journal of Clinical Oncology 30:1, 45-50
CrossRef155
Christina Pfannenberg, Philip Aschoff, Sandra Schanz, Susanne M. Eschmann, Christian Plathow, Thomas K. Eigentler, Claus Garbe, Klaus Brechtel, Reinhard Vonthein, Roland Bares, Claus D. Claussen, Heinz P. Schlemmer. (2007) Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. European Journal of Cancer 43:3, 557-564
CrossRef156
A. Devaraj, G.J.R. Cook, D.M. Hansell. (2007) PET/CT in non-small cell lung cancer staging—promises and problems. Clinical Radiology 62:2, 97-108
CrossRef157
S.M. Eschmann, G. Friedel, F. Paulsen, M. Reimold, T. Hehr, W. Budach, H. Dittmann, H.-J. Langen, R. Bares. (2007) Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 55:2, 165-171
CrossRef158
Juan Carlos Peñalver Cuesta, Carlos Jordá Aragón, Juan Escrivá Peiró, José Cerón Navarro, Víctor Calvo Medina, José Padilla Alarcón. (2007) Trasplante pulmonar. Carcinoma broncogénico en pulmón nativo. Archivos de Bronconeumología 43:2, 126-128
CrossRef159
S. M. Eschmann, G. Friedel, F. Paulsen, M. Reimold, T. Hehr, J. Scheiderbauer, W. Budach, J. Kotzerke, R. Bares. (2007) Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors. European Journal of Nuclear Medicine and Molecular Imaging 34:1, 54-59
CrossRef160
Michalis Aristophanous, Bill C. Penney, Mary K. Martel, Charles A. Pelizzari. (2007) A Gaussian mixture model for definition of lung tumor volumes in positron emission tomography. Medical Physics 34:11, 4223
CrossRef161
Laura Drever, Wilson Roa, Alexander McEwan, Don Robinson. (2007) Iterative threshold segmentation for PET target volume delineation. Medical Physics 34:4, 1253
CrossRef162
Anna C. Pfannenberg, Philip Aschoff, Klaus Brechtel, Mark Müller, Roland Bares, Frank Paulsen, Jutta Scheiderbauer, Godehard Friedel, Claus D. Claussen, Susanne M. Eschmann. (2007) Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 34:1, 36-44
CrossRef163
N. A. Shkumat, J. H. Siewerdsen, A. C. Dhanantwari, D. B. Williams, S. Richard, N. S. Paul, J. Yorkston, R. Van Metter. (2007) Optimization of image acquisition techniques for dual-energy imaging of the chest. Medical Physics 34:10, 3904
CrossRef164
Lioe-Fee de Geus-Oei, J. Han J.M. van Krieken, Riena P. Aliredjo, Paul F.M. Krabbe, Cathelijne Frielink, Ad F.T. Verhagen, Otto C. Boerman, Wim J.G. Oyen. (2007) Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55:1, 79-87
CrossRef165
Michelle S. Ginsberg, Ravinder K. Grewal, Robert T. Heelan. (2007) Lung Cancer. Radiologic Clinics of North America 45:1, 21-43
CrossRef166
Won Woo Lee, Jin-Haeng Chung, Sung-June Jang, Jae Seon Eo, So Yeon Park, Sook Whan Sung, Young So, June-Key Chung, Myung Chul Lee, Sang Eun Kim. (2006) Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET. Journal of Surgical Oncology 94:7, 607-613
CrossRef167
M. A. Saksena, J. Y. Kim, M. G. Harisinghani. (2006) Nodal staging in genitourinary cancers. Abdominal Imaging 31:6, 644-651
CrossRef168
Priyajit Prasad, Johannes Wittmann, Stephen P. Pereira. (2006) Endoscopic Ultrasound of the Upper Gastrointestinal Tract and Mediastinum: Diagnosis and Therapy. CardioVascular and Interventional Radiology 29:6, 947-957
CrossRef169
K. Ott, W. Weber, J.-R. Siewert. (2006) The importance of PET in the diagnosis and response evaluation of esophageal cancer. Diseases of the Esophagus 19:6, 433-442
CrossRef170
J.-H. Chung, W.W. Lee, S.Y. Park, G. Choe, S.W. Sung, J.-K. Chung, M.C. Lee, S.E. Kim. (2006) FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. European Journal of Surgical Oncology (EJSO) 32:9, 989-995
CrossRef171
Aarati Ranganathan, Alex Adjei, Primo Lara. (2006) 2006 Highlights From: The European Society for Medical Oncology Congress Istanbul, Turkey; Sept. 29-Oct. 3, 2006 International Association for the Study of Lung Cancer Early Invasive Lung Cancer Workshop Turin, Italy; Sept. 25–26, 2006. Clinical Lung Cancer 8:3, 170-178
CrossRef172
Glòria Fernández-Esparrach, Angels Ginès, Josep Belda, Maria Pellisé, Manel Solé, Ramón Marrades, Oriol Sendino, Lluís Colomo, Alfredo Mata, Josep Llach, Josep M. Bordas, Antoni Castells. (2006) Transesophageal ultrasound-guided fine needle aspiration improves mediastinal staging in patients with non-small cell lung cancer and normal mediastinum on computed tomography. Lung Cancer 54:1, 35-40
CrossRef173
Jokke Wynants, Sigrid Stroobants, Christophe Dooms, Johan Vansteenkiste. (2006) Staging of Lung Cancer. PET Clinics 1:4, 301-316
CrossRef174
Chao Hui Huang, Douglas H. McGregor, Vynette Haltaufderhyde, Frank Victor, Peter VanVeldhuizen. (2006) Dysgenetic hypoplastic kidney simulating metastatic lung carcinoma. Lung Cancer 54:1, 125-129
CrossRef175
K. ALZAHOURI, Y. MARTINET, S. BRIANÇON, F. GUILLEMIN. (2006) Staging practices of primary non-small-cell lung cancer: a literature review. European Journal of Cancer Care 15:4, 348-354
CrossRef176
Henk Kramer, Joyce Sanders, Wendy J. Post, Harry J.M. Groen, Albert J.H. Suurmeijer. (2006) Analysis of cytological specimens from mediastinal lesions obtained by endoscopic ultrasound-guided fine-needle aspiration. Cancer 108:4, 206-211
CrossRef177
Gustavo Souza Portes Meirelles, Gregory Ravizzini, Andre Luis Moreira, Timothy Akhurst. (2006) Primary Pulmonary Meningioma Manifesting as a Solitary Pulmonary Nodule With a False-positive PET Scan. Journal of Thoracic Imaging 21:3, 225-227
CrossRef178
G. Fernandes, M. Sucena, E. Lombardia, A. Machado, V. Hespanhol, H. Queiroga, Doutor J. Agostinho Marques. (2006) Cancro do pulmão de não pequenas células – Comparação entre o estadiamento clínico e o patológico. Revista Portuguesa de Pneumologia (English Edition) 12:4, 337-357
CrossRef179
Alain Luciani, Emmanuel Itti, Alain Rahmouni, Michel Meignan, Olivier Clement. (2006) Lymph node imaging: Basic principles. European Journal of Radiology 58:3, 338-344
CrossRef180
Gerwin P. Schmidt, Alexander R. Haug, Stefan O. Schoenberg, Maximilian F. Reiser. (2006) Whole-body MRI and PET-CT in the management of cancer patients. European Radiology 16:6, 1216-1225
CrossRef181
Katherine S. Virgo, Keith S. Naunheim, Frank E. Johnson. (2006) Preoperative Workup and Postoperative Surveillance for Patients Undergoing Pulmonary Metastasectomy. Thoracic Surgery Clinics 16:2, 125-131
CrossRef182
John F. Bruzzi, Reginald F. Munden. (2006) PET/CT Imaging of Lung Cancer. Journal of Thoracic Imaging 21:2, 123-136
CrossRef183
Mylene T. Truong, Tinsu Pan, Jeremy J. Erasmus. (2006) Pitfalls in Integrated CT-PET of the Thorax: Implications in Oncologic Imaging. Journal of Thoracic Imaging 21:2, 111-122
CrossRef184
Eric D. Bernstein, Scott M. Herbert, Nasser H. Hanna. (2006) Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer. Annals of Surgical Oncology 13:3, 291-301
CrossRef185
S. M. Eschmann, G. Friedel, F. Paulsen, M. Reimold, T. Hehr, W. Budach, J. Scheiderbauer, H. J. Machulla, H. Dittmann, R. Vonthein, R. Bares. (2006) Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?. European Journal of Nuclear Medicine and Molecular Imaging 33:3, 263-269
CrossRef186
Giancarlo Pillot, Barry A. Siegel, Ramaswamy Govindan. (2006) Prognostic Value of Fluorodeoxyglucose Positron Emission Tomography in Non-small Cell Lung Cancer: A Review. Journal of Thoracic Oncology 1:2, 152-159
CrossRef187
A. Cahid Civelek, Bryan Piotrowski, Medhat M. Osman, Esat Memisoglu, Nael Khayyat, Hans Joachim Reimers, Keith S. Naunheim. (2006) Cutaneous metastatic lung cancer detected with18F-FDG PET. Annals of Nuclear Medicine 20:2, 147-149
CrossRef188
Olivia Will, Sanjay Purkayastha, Christopher Chan, Thanos Athanasiou, Ara W Darzi, Wady Gedroyc, Paris P Tekkis. (2006) Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. The Lancet Oncology 7:1, 52-60
CrossRef189
Su-Ying LOW, Philip ENG, Gilbert H.W. KENG, David C.E. NG. (2006) Positron emission tomography with CT in the evaluation of non-small cell lung cancer in populations with a high prevalence of tuberculosis. Respirology 11:1, 84-89
CrossRef190
Katherine E. Posther, David H. Harpole. (2006) The Surgical Management of Lung Cancer. Cancer Investigation 24:1, 56-67
CrossRef191
Laura Drever, Don M. Robinson, Alexander McEwan, Wilson Roa. (2006) A local contrast based approach to threshold segmentation for PET target volume delineation. Medical Physics 33:6, 1583
CrossRef192
Johan F. Vansteenkiste, Sigrid S. Stroobants. (2006) PET Scan in Lung Cancer: Current Recommendations and Innovation. Journal of Thoracic Oncology 1:1, 71-73
CrossRef193
Brian Yaremko, Terence Riauka, Don Robinson, Brad Murray, Abraham Alexander, Alexander McEwan, Wilson Roa. (2005) Thresholding in PET images of static and moving targets. Physics in Medicine and Biology 50:24, 5969-5982
CrossRef194
Jeffrey L. Port, Rafael S. Andrade, Matthew A. Levin, Robert J. Korst, Paul C. Lee, David E. Becker, Nasser K. Altorki. (2005) Positron emission tomographic scanning in the diagnosis and staging of non–small cell lung cancer 2 cm in size or less. The Journal of Thoracic and Cardiovascular Surgery 130:6, 1611-1615
CrossRef195
Kazuhiro Yasufuku, Masako Chiyo, Eitetsu Koh, Yasumitsu Moriya, Akira Iyoda, Yasuo Sekine, Kiyoshi Shibuya, Toshihiko Iizasa, Takehiko Fujisawa. (2005) Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer 50:3, 347-354
CrossRef196
Gerwin P. Schmidt, Andrea Baur-Melnyk, Peter Herzog, Rupert Schmid, Reinhold Tiling, Michael Schmidt, Maximilian F. Reiser, Stefan O. Schoenberg. (2005) High-Resolution Whole-Body Magnetic Resonance Image Tumor Staging With the Use of Parallel Imaging Versus Dual-Modality Positron Emission Tomography???Computed Tomography. Investigative Radiology 40:12, 743-753
CrossRef197
Fernando Cordera, Walter Scott. (2005) Lymphatic Drainage Patterns of Thoracic Malignancies. Journal of Bronchology 12:4, 254-266
CrossRef198
Kelvin K. Yap, Kenneth S. K. Yap, Amanda J. Byrne, Salvatore U. Berlangieri, Aurora Poon, Paul Mitchell, Simon R. Knight, Peter C. Clarke, Anthony Harris, Andrew Tauro, Christopher C. Rowe, Andrew M. Scott. (2005) Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 32:9, 1033-1040
CrossRef199
B. Zane Atkins, Thomas A. D’Amico. (2005) Controversial Issues Regarding the Use of Induction Chemotherapy for Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 17:3, 191-194
CrossRef200
S. Marnitz, P. Messer, M. Stuschke, C. Pöttgen, W. Hinkelbein. (2005) Einsatz der PET-CT zur Verbesserung der Bestrahlungsplanung nichtkleinzelliger Bronchialkarzinome. Der Onkologe 11:8, 859-865
CrossRef201
Katsumi Hayashi, Katsumi Abe, Fuzuki Yano, Sadahiro Watanabe, Yoshie Iwasaki, Shigeru Kosuda. (2005) Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?. Annals of Nuclear Medicine 19:5, 393-398
CrossRef202
Robert James Cerfolio, Ayesha S. Bryant, Buddhiwardhan Ohja, Alfred A. Bartolucci. (2005) The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. The Journal of Thoracic and Cardiovascular Surgery 130:1, 151-159
CrossRef203
Suzanne L. Aquino. (2005) Imaging of Metastatic Disease to the Thorax. Radiologic Clinics of North America 43:3, 481-495
CrossRef204
Brian Yaremko, Terence Riauka, Donald Robinson, Brad Murray, Alexander McEwan, Wilson Roa. (2005) Threshold modification for tumour imaging in non-small-cell lung cancer using positron emission tomography. Nuclear Medicine Communications 26:5, 433-440
CrossRef205
Stanley J. Goldsmith, Lale A. Kostakoglu, Serge Somrov, Christopher J. Palestro. (2005) Radionuclide Imaging of Thoracic Malignancies. Radiologic Clinics of North America 43:3, 571-588
CrossRef206
R BENAMORE, S CHIPPINGTON, J ENTWISLE. (2005) The value of performing head CT in screening for cerebral metastases in patients with potentially resectable non-small cell lung cancer: experience from a UK cardiothoracic centre. Clinical Radiology 60:5, 619-620
CrossRef207
K ALZAHOURI, C LEJEUNE, M WORONOFFLEMSI, P ARVEUX, F GUILLEMIN. (2005) Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clinical Radiology 60:4, 479-492
CrossRef208
Thomas A. Hensing. (2005) Clinical Evaluation and Staging of Patients Who Have Lung Cancer. Hematology/Oncology Clinics of North America 19:2, 219-235
CrossRef209
Quynh-Thu Le, David W. Petrik. (2005) Nonsurgical Therapy for Stages I and II Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America 19:2, 237-261
CrossRef210
D. Ukena, D. Hellwig. (2005) Diagnostik des Bronchialkarzinoms. Der Pneumologe 2:2, 111-117
CrossRef211
Alex Rosioreanu, Betty Motroni, Asante Dickson, Elizabeth Yung. (2005) 18F-FDG PET Application for Malignancies in Women. Journal of Women's Imaging 7:1, 1-15
CrossRef212
Kazuya Takamochi, Junji Yoshida, Koji Murakami, Seiji Niho, Genichiro Ishii, Mitsuyo Nishimura, Yutaka Nishiwaki, Kazuya Suzuki, Kanji Nagai. (2005) Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 47:2, 235-242
CrossRef213
Sietske A. Smulders, Frank W.J.M. Smeenk, Maryska L.G. Janssen-Heijnen, Pascal L.M.L. Wielders, Dirk R.A.J. de Munck, Pieter E. Postmus. (2005) Surgical mediastinal staging in daily practice. Lung Cancer 47:2, 243-251
CrossRef214
Avraham Eisbruch. (2005) Intensity-modulated radiation therapy in the treatment of head and neck cancer. Nature Clinical Practice Oncology 2:1, 34-39
CrossRef215
Mohamad A. Eloubeidi, Robert J. Cerfolio, Victor K. Chen, Renee Desmond, Sujath Syed, Buddhiwardhan Ojha. (2005) Endoscopic Ultrasound-Guided Fine Needle Aspiration of Mediastinal Lymph Node in Patients With Suspected Lung Cancer After Positron Emission Tomography and Computed Tomography Scans. The Annals of Thoracic Surgery 79:1, 263-268
CrossRef216
Smith Apisarnthanarax, K. S. Clifford Chao. (2005) Current Imaging Paradigms in Radiation Oncology. Radiation Research 163:1, 1-25
CrossRef217
Özcan Birim, A. Pieter Kappetein, Theo Stijnen, Ad J.J.C. Bogers. (2005) Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer. The Annals of Thoracic Surgery 79:1, 375-382
CrossRef218
Kenneth B. Roberts, Michael P. Mac Manus, Rodney J. Hicks, Danny Rischin, Andrew Wirth, Gavin M. Wright, David L. Ball. (2005) PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. Lung Cancer 47:1, 49-57
CrossRef219
Robert J. Cerfolio, Ayesha S. Bryant, Thomas S. Winokur, Buddhiwardhan Ohja, Alfred A. Bartolucci. (2004) Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 78:6, 1903-1909
CrossRef220
Ruairi J. Fahy, Mark King. (2004) Fluorodeoxyglucose F 18 Positron Emission Tomography Scanning in Thoracic Disease. Southern Medical Journal 97:12, 1156-1157
CrossRef221
I. Brink, T. Schumacher, M. Mix, S. Ruhland, E. Stoelben, W. Digel, M. Henke, N. Ghanem, E. Moser, E. U. Nitzsche. (2004) Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 31:12, 1614-1620
CrossRef222
P. Herzog, B. Scher, T. Helmberger, K. Hahn, M. F. Reiser, C. R. Becker. (2004) PET-CT und interventionelle Tumortherapie. Der Radiologe 44:11, 1088-1095
CrossRef223
G. P. Schmidt, R. Schmid, K. Hahn, M. F. Reiser. (2004) Ganzk
rper-MRT und PET-CT in der Tumordiagnostik. Der Radiologe 44:11, 1079-1087
CrossRef224
Johan Vansteenkiste, Barbara M Fischer, Christophe Dooms, Jann Mortensen. (2004) Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. The Lancet Oncology 5:9, 531-540
CrossRef225
Yaron Shargall, Marc de Perrot, Shaf Keshavjee, Gail Darling, Robert Ginsberg, Michael Johnston, Andrew Pierre, Thomas K. Waddell. (2004) 15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer. Lung Cancer 45:3, 357-363
CrossRef226
Robert James Cerfolio, Buddhiwardhani Ojha, Ayesha S. Bryant, Vanguru Raghuveer, James M. Mountz, Alfred A. Bartolucci. (2004) The accuracy of integrated PET-CT compared with dedicated pet alone for the staging of patients with nonsmall cell lung cancer. The Annals of Thoracic Surgery 78:3, 1017-1023
CrossRef227
Arifa Pasic, Pieter E. Postmus, Thomas G. Sutedja. (2004) What is early lung cancer?. Lung Cancer 45:3, 267-277
CrossRef228
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Lynch, Thomas J., Wright, Cameron D., Choi, Noah C., Aquino, Suzanne L., Mark, Eugene J., . (2004) Case 26-2004. New England Journal of Medicine 351:8, 809-817
Full Text229
Wim JG Oyen, Jan Bussink, Ad FT Verhagen, Frans HM Corstens, Gerben P Bootsma. (2004) Role of FDG-PET in the diagnosis and management of lung cancer. Expert Review of Anticancer Therapy 4:4, 561-567
CrossRef230
Michael Semik, Barbara Netz, Christoph Schmidt, Hans Heinrich Scheld. (2004) Surgical exploration of the mediastinum: mediastinoscopy and intraoperative staging. Lung Cancer 45, S55-S61
CrossRef231
D. Ukena, D. Hellwig. (2004) Value of FDG PET in the management of NSCLC. Lung Cancer 45, S75-S78
CrossRef232
Johny A Verschakelen, Walter De Wever, Jan Bogaert. (2004) Role of computed tomography in lung cancer staging. Current Opinion in Pulmonary Medicine 10:4, 248-255
CrossRef233
S. S. Foo, P. L. Mitchell, S. U. Berlangieri, C. L. Smith, A. M. Scott. (2004) Positron emission tomography scanning in the assessment of patients with lymphoma. Internal Medicine Journal 34:7, 388-397
CrossRef234
Sendhil Kumar Cheran, James E Herndon, Edward F Patz. (2004) Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 44:3, 317-325
CrossRef235
(2004) Multidisciplinary Management of Lung Cancer. New England Journal of Medicine 350:19, 2008-2010
Full Text236
A.F.T. Verhagen, G.P. Bootsma, V.C.G. Tjan-Heijnen, G.J. van der Wilt, A.L. Cox, M.H.J. Brouwer, F.H.M. Corstens, W.J.G. Oyen. (2004) FDG-PET in staging lung cancer. Lung Cancer 44:2, 175-181
CrossRef237
L.M. Kenny, E.O. Aboagye, P.M. Price. (2004) Positron Emission Tomography Imaging of Cell Proliferation in Oncology. Clinical Oncology 16:3, 176-185
CrossRef238
J.T. Annema, O.S. Hoekstra, E.F. Smit, M. Veseliç, M.I.M. Versteegh, K.F. Rabe. (2004) Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. Lung Cancer 44:1, 53-60
CrossRef239
Glenn P. Ollenberger, Aurora M. T. Poon. (2004) Hydropneumothorax on FDG PET Imaging. Clinical Nuclear Medicine 29:4, 277-278
CrossRef240
Alan D.L Sihoe, Anthony P.C Yim. (2004) Lung cancer staging. Journal of Surgical Research 117:1, 92-106
CrossRef241
Johan F Vansteenkiste, Sigrid G Stroobants. (2004) Positron emission tomography in the management of non–small cell lung cancer. Hematology/Oncology Clinics of North America 18:1, 269-288
CrossRef242
Wood, Alastair J.J., , Spira, Alexander, Ettinger, David S., . (2004) Multidisciplinary Management of Lung Cancer. New England Journal of Medicine 350:4, 379-392
Full Text243
Don Robinson, Isabelle Gagne, Terence Riauka, John Duke, Wilson Roa. (2004) Metallic copper as a fiducial marker for both CT and PET. Medical Physics 31:9, 2520
CrossRef244
PM Logan. (2004) Lung cancer audit in an Irish teaching hospital. Irish Journal of Medical Science 173:1, 7-8
CrossRef245
Konstantin J Dedes, Thomas D Szucs, Stephan Bodis, Markus Joerger, Adam Lowy, Erich W Russi, Hans C Steinert, Walter Weder, Rolf A Stahel. (2004) Management and Costs of Treating Lung Cancer Patients in a University Hospital. PharmacoEconomics 22:7, 435-444
CrossRef246
Jeffrey L Port, Michael S Kent, Robert J Korst, Roger Keresztes, Matthew A Levin, Nasser K Altorki. (2004) Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. The Annals of Thoracic Surgery 77:1, 254-259
CrossRef247
Gonzalo V Gonzalez-Stawinski, Anthony Lemaire, Faisal Merchant, Elizabeth O'Halloran, R.Edward Coleman, David H Harpole, Thomas A D'Amico. (2003) A comparative analysis of positron emission tomography and mediastinoscopy in staging non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 126:6, 1900-1904
CrossRef248
Martin Hetzel, Coskun Arslandemir, Hans-Helmut König, Andreas K Buck, Karin Nüssle, Gerhard Glatting, Andreas Gabelmann, JÜRgen Hetzel, Vinzenz Hombach, Holger Schirrmeister. (2003) F-18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost-Effectiveness, and Impact on Patient Management. Journal of Bone and Mineral Research 18:12, 2206-2214
CrossRef249
Kemp H. Kernstine. (2003) Positron emission tomography with 2-[18f]fluoro-2-deoxy-d-glucose: can it be used to accurately stage the mediastinum in non–small cell lung cancer as an alternative to mediastinoscopy?. The Journal of Thoracic and Cardiovascular Surgery 126:6, 1700-1703
CrossRef250
Johan F. Vansteenkiste. (2003) PET scan in the staging of non-small cell lung cancer. Lung Cancer 42:2, 27-37
CrossRef251
U. Pastorino, G Veronesi, C Landoni, M Leon, M Picchio, P.G Solli, F Leo, L Spaggiari, G Pelosi, M Bellomi, F Fazio. (2003) Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis. The Journal of Thoracic and Cardiovascular Surgery 126:6, 1906-1910
CrossRef252
Giorgio Scagliotti, Silvia Novello. (2003) Adjuvant chemotherapy after complete resection for early stage NSCLC. Lung Cancer 42:2, 47-51
CrossRef253
N DELAHAYE, B CRESTANI, H RAKOTONIRINA, R LEBTAHI, L SARDA, P GIRARD, E CHARPENTIER, E FERY-LEMONNIER, A SYROTA, M AUBIER, D LE GULUDEC. (2003) Comparative impact of standard approach, FDG PET and FDG dual-head coincidence gamma camera imaging in preoperative staging of patients with non-small-cell lung cancer. Nuclear Medicine Communications 24:12, 1215-1224
CrossRef254
Carolyn E Reed, David H Harpole, Katherine E Posther, Sandra L Woolson, Robert J Downey, Bryan F Meyers, Robert T Heelan, Homer A MacApinlac, Sin-Ho Jung, Gerard A Silvestri, Barry A Siegel, Valerie W Rusch. (2003) Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 126:6, 1943-1951
CrossRef255
Pieter E Postmus, Pierre Rocmans, Hisao Asamura, David Ball, José Belderbos, Matteo Cappello, Jacek Jassem, Silvia Novello, Harvey Pass, Bernward Passlick, Robert Pirker, Neal Ready, William Sause, Giorgio Scagliotti, Johan Vansteenkiste, Virginie Westeel, Nico van Zandwijk. (2003) Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. Lung Cancer 42:2, 3-6
CrossRef256
Jeffrey J. Peterson, Mark J. Kransdorf, Mary I. O???Connor. (2003) Diagnosis of Occult Bone Metastases: Positron Emission Tomography. Clinical Orthopaedics and Related Research 415, S120-S128
CrossRef257
(2003) Staging of Non–Small-Cell Lung Cancer with Integrated PET and CT. New England Journal of Medicine 349:12, 1188-1190
Full Text258
Mitchell Machtay, Branislav Jeremic. (2003) Complex and controversial issues in locally advanced non-small cell lung carcinoma. Seminars in Surgical Oncology 21:2, 128-137
CrossRef259
Robert J Cerfolio, Buddhiwardhan Ojha, Ayesha S Bryant, Cynthia S Bass, Alfred A Bartalucci, James M Mountz. (2003) The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. The Annals of Thoracic Surgery 76:3, 861-866
CrossRef260
Michael Y. Chang, David J. Sugarbaker. (2003) Surgery for early stage non-small cell lung cancer. Seminars in Surgical Oncology 21:2, 74-84
CrossRef261
Kenneth E. Rosenzweig, Howard Amols, C.C. Ling. (2003) New radiotherapy technologies. Seminars in Surgical Oncology 21:3, 190-195
CrossRef262
Giorgio V. Scagliotti, Silvia Novello. (2003) Adjuvant therapy in completely resected non-small-cell lung cancer. Current Oncology Reports 5:4, 318-325
CrossRef263
Henk Kramer, Harry J.M. Groen. (2003) Current Concepts in the Mediastinal Lymph Node Staging of Nonsmall Cell Lung Cancer. Annals of Surgery 238:2, 180-188
CrossRef264
Suzanne L. Aquino, Jane C. Asmuth, Nathaniel M. Alpert, Elkan F. Halpern, Alan J. Fischman. (2003) Improved Radiologic Staging of Lung Cancer with 2-[18F]-Fluoro-2-Deoxy-d-Glucose–Positron Emission Tomography and Computed Tomography Registration. Journal of Computer Assisted Tomography 27:4, 479-484
CrossRef265
Suzanne L. Aquino, L. Anne Hayman, Susanne L. Loomis, Katherine H. Taber. (2003) The Source and Direction of Thoracic Lymphatics, Part II: The Lower Thorax. Journal of Computer Assisted Tomography 27:4, 657-661
CrossRef266
Lardinois, Didier, Weder, Walter, Hany, Thomas F., Kamel, Ehab M., Korom, Stephan, Seifert, Burkhardt, von Schulthess, Gustav K., Steinert, Hans C., . (2003) Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed Tomography. New England Journal of Medicine 348:25, 2500-2507
Full Text267
J.Hugo Schouwink, Leo Schultze Kool, Emiel J Rutgers, Frans A.N Zoetmulder, Nico van Zandwijk, Marc J v.d. Vijver, Paul Baas. (2003) The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. The Annals of Thoracic Surgery 75:6, 1715-1718
CrossRef268
Giorgio V. Scagliotti, Silvia Novello. (2003) The dream is almost over…don't worry, look ahead. Lung Cancer 40:2, 187-190
CrossRef269
Didier Lardinois, Alex Schallberger, Daniel Betticher, Hans-Beat Ris. (2003) Postinduction video-mediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non–small cell lung cancer. The Annals of Thoracic Surgery 75:4, 1102-1106
CrossRef270
U. Lassen, G. Daugaard, A. Eigtved, L. Højgaard, K. Damgaard, M. Rørth. (2003) Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. European Journal of Nuclear Medicine and Molecular Imaging 30:3, 396-402
CrossRef271
Suzanne L. Aquino, L. Anne Hayman, Susanne L. Loomis, Katherine H. Taber. (2003) Source and Direction of Thoracic Lymphatics: Part I—Upper Thorax. Journal of Computer Assisted Tomography 27:2, 292-296
CrossRef272
Tracey L. Evans, Thomas J. Lynch. (2003) Recent Advances in the Treatment of Stage IIIA Lung Cancer. Clinical Pulmonary Medicine 10:2, 100-110
CrossRef273
D. Visvikis, D. C. Costa, I. Croasdale, A. H. R. Lonn, J. Bomanji, S. Gacinovic, P. J. Ell. (2003) CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. European Journal of Nuclear Medicine and Molecular Imaging 30:3, 344-353
CrossRef274
Yong Soo Choi, Young Mog Shim, Jhingook Kim, Kwhanmien Kim. (2003) Mediastinoscopy in patients with clinical stage I non–small cell lung cancer. The Annals of Thoracic Surgery 75:2, 364-366
CrossRef275
Gunnar Myrdal, Mats Lambe, Gunnar Gustafsson, Kristina Nilsson, Elisabeth Ståhle. (2003) Survival in primary lung cancer potentially cured by operation: influence of tumor stage and clinical characteristics. The Annals of Thoracic Surgery 75:2, 356-363
CrossRef276
Kotaro Higashi, Ichiro Matsunari, Yoshimichi Ueda, Ryosuke Ikeda, Jianfei Guo, Manabu Oguchi, Hisao Tonami, Itaru Yamamoto. (2003) Value of whole-body FDG PET in management of lung cancer. Annals of Nuclear Medicine 17:1, 1-14
CrossRef277
Ichiro Hasegawa, Keisuke Eguchi, Ehiichi Kohda, Yutaka Tanami, Toru Mori, Hiroto Hatabu, Sachio Kuribayashi. (2003) Pulmonary hilar lymph nodes in lung cancer: assessment with 3D-dynamic contrast-enhanced MR imaging. European Journal of Radiology 45:2, 129-134
CrossRef278
Sigrid Stroobants, Johny Verschakelen, Johan Vansteenkiste. (2003) Value of FDG-PET in the management of non-small cell lung cancer. European Journal of Radiology 45:1, 49-59
CrossRef279
Z.C Traill, F.V Gleeson. (2003) Bronchoscopy and surgical staging procedures and their correlation with imaging. European Journal of Radiology 45:1, 39-48
CrossRef280
James D. Luketich. (2003) Diagnostic Imaging and Other Tools in the Detection of Lung Cancer. Clinical Lung Cancer 4:4, 248
CrossRef281
Sharyn L.S MacDonald, David M Hansell. (2003) Staging of non-small cell lung cancer: imaging of intrathoracic disease. European Journal of Radiology 45:1, 18-30
CrossRef282
R. A. SCHMID, H. HAUTMANN, B. POELLINGER, W. KELLNER, A. MOISSEEV, K. BRINKBAEUMER, M. WEISS, K. HAHN, S. DRESEL. (2003) Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET). Nuclear Medicine Communications 24:1, 37-45
CrossRef283
C.J Beadsmoore, N.J Screaton. (2003) Classification, staging and prognosis of lung cancer. European Journal of Radiology 45:1, 8-17
CrossRef284
GERARDA J. M. HERDER, ALLE WELLING, GRISCHA V. DE WINTER, EMILE F. I. COMANS, OTTO S. HOEKSTRA. (2003) Accessory Findings on F-18 FDG Positron Emission Tomography in Bronchogenic Carcinoma. Clinical Nuclear Medicine 28:1, 58-59
CrossRef285
H. J. M. Groen. (2002) Positron Emission Tomography in Lung Cancer. Imaging Decisions MRI 6:4, 23-25
CrossRef286
Giorgio Scagliotti. (2002) Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages. Lung Cancer 38, 23-29
CrossRef287
U Pastorino. (2002) Extended resections for lung cancer: indications and results. Surgical Oncology 11:4, 207-216
CrossRef288
J. Czernin. (2002) Clinical Applications of FDG-PET in Oncology. Acta Medica Austriaca 29:5, 162-170
CrossRef289
Nico van Zandwijk. (2002) New methods for early diagnosis of lung cancer. Lung Cancer 38:1, S9-S11
CrossRef290
Ulrik Lassen. (2002) FDG-PET imaging in small cell lung cancer: any value?. Lung Cancer 37:1, 7
CrossRef291
David T. Price, R. Edward Coleman, Ray P. Liao, Cary N. Robertson, Thomas J. Polascik, Timothy R. Degrado. (2002) Comparison of [18F]Fluorocholine and [18F]Fluorodeoxyglucose for Positron Emission Tomography of Androgen Dependent and Androgen Independent Prostate Cancer. The Journal of Urology 168:1, 273-280
CrossRef292
Cordula C.M Pitz, Klaartje W Maas, Henry A.Van Swieten, Aart Brutel de la Rivière, Pieter Hofman, Franz M.N.H Schramel. (2002) Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer. The Annals of Thoracic Surgery 74:1, 164-169
CrossRef293
DAVID T. PRICE, R. EDWARD COLEMAN, RAY P. LIAO, CARY N. ROBERTSON, THOMAS J. POLASCIK, TIMOTHY R. deGRADO. (2002) Comparison of [18F]Fluorocholine and [18F]Fluorodeoxyglucose for Positron Emission Tomography of Androgen Dependent and Androgen Independent Prostate Cancer. The Journal of Urology273-280
CrossRef294
Thomas A D’Amico, Terence Z Wong, David H Harpole, Stephen D Brown, R.Edward Coleman. (2002) Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies. The Annals of Thoracic Surgery 74:1, 160-163
CrossRef295
Priscilla S. A. Sarinas, Rajinder K. Chitkara. (2002) PET and SPECT in the management of lung cancer. Current Opinion in Pulmonary Medicine 8:4, 257-264
CrossRef296
John M. Barker, Gerard A. Silvestri. (2002) Lung cancer staging. Current Opinion in Pulmonary Medicine 8:4, 287-293
CrossRef297
Robert Chin, Trent W. McCain, Antonius A. Miller, Donnie P. Dunagan, Jose Acostamadiedo, L. Douglas Case, Beth A. Harkness, Lee P. Adler, Edward F. Haponik. (2002) Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 37:1, 1-6
CrossRef298
Michael J Morris, Timothy Akhurst, Iman Osman, Rodolfo Nunez, Homer Macapinlac, Karen Siedlecki, David Verbel, Lawrence Schwartz, Steven M Larson, Howard I Scher. (2002) Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59:6, 913-918
CrossRef299
Richard H Feins. (2002) Multi-modality treatment of non-small cell lung cancer. Surgical Clinics of North America 82:3, 611-620
CrossRef300
Bernard J Park, Nasser K Altorki. (2002) Diagnosis and management of early lung cancer. Surgical Clinics of North America 82:3, 457-476
CrossRef301
Walter J. Scott. (2002) Positron emission tomography (PET) and combined imaging modalities for staging lung cancer. Surgical Clinics of North America 82:3, 477-495
CrossRef302
Harm van Tinteren, Otto S Hoekstra, Egbert F Smit, Jan HAM van den Bergh, Ad JM Schreurs, Roland ALM Stallaert, Piet CM van Velthoven, Emile FI Comans, Fred W Diepenhorst, Paul Verboom, Johan C van Mourlk, Pieter E Postmus, Maarten Boers, Gerrit JJ Teule. (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. The Lancet 359:9315, 1388-1392
CrossRef303
R Edward Coleman. (2002) Value of FDG-PET scanning in management of lung cancer. The Lancet 359:9315, 1361-1362
CrossRef304
Gianfranco Buccheri, Alberto Biggi, Domenico Ferrigno, Antonella Francini. (2002) 99mTC-tetrofosmin scintigraphy in lung carcinoma staging and follow-up evaluations. Cancer 94:6, 1796-1807
CrossRef305
Clifton F Mountain. (2002) Staging classification of lung cancer: A Critical Evaluation. Clinics in Chest Medicine 23:1, 103-121
CrossRef306
Tracey L. Evans, Dean M. Donahue, Douglas J. Mathisen, Thomas J. Lynch. (2002) Building a better therapy for stage IIIA non-small cell lung cancer. Clinics in Chest Medicine 23:1, 191-207
CrossRef307
Theresa C McLoud. (2002) Imaging techniques for diagnosis and staging of lung cancer. Clinics in Chest Medicine 23:1, 123-136
CrossRef308
Johannes Czernin, Michael E. Phelps. (2002) P
OSITRON EMISSION TOMOGRAPHY SCANNING : Current and Future Applications. Annual Review of Medicine 53:1, 89-112
CrossRef309
John D Minna, Jack A Roth, Adi F Gazdar. (2002) Focus on lung cancer. Cancer Cell 1:1, 49-52
CrossRef310
Kemp H Kernstine, Kelley A McLaughlin, Yusuf Menda, Nicholas P Rossi, Daniel J Kahn, David L Bushnell, Michael M Graham, Carl K Brown, Mark T Madsen. (2002) Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?. The Annals of Thoracic Surgery 73:2, 394-402
CrossRef311
Tomio Inoue, Noboru Oriuchi, Katsumi Tomiyoshi, Keigo Endo. (2002) A shifting landseape: What will be next FDG in PET oncology?. Annals of Nuclear Medicine 16:1, 1-9
CrossRef312
Gavin C. Harewood, Maurits J. Wiersema, Eric S. Edell, Mark Liebow. (2002) Cost-Minimization Analysis of Alternative Diagnostic Approaches in a Modeled Patient With Non-Small Cell Lung Cancer and Subcarinal Lymphadenopathy. Mayo Clinic Proceedings 77:2, 155-164
CrossRef313
G. C. Harewood, M. J. Wiersema, E. S. Edell, M. Liebow. (2002) Cost-Minimization Analysis of Alternative Diagnostic Approaches in a Modeled Patient With Non-Small Cell Lung Cancer and Subcarinal Lymphadenopathy. Mayo Clinic Proceedings 77:2, 155-164
CrossRef314
Vikas Batra, Gregory C. Kane, Sandra Weibel. (2002) Preoperative Evaluation of Patients with Lung Cancer Undergoing Thoracic Surgery. Clinical Pulmonary Medicine 9:1, 46-52
CrossRef315
Kazuo Kubota. (2001) From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology. Annals of Nuclear Medicine 15:6, 471-486
CrossRef316
David A Waller. (2001) Surgery for non-small cell lung cancer—new trends. Lung Cancer 34, S133-S136
CrossRef317
Andrea Frilling, Karsten Tecklenborg, Rainer Görges, Frank Weber, Malte Clausen, Erich Christoph Broelsch. (2001) Preoperative Diagnostic Value of [18F] Fluorodeoxyglucose Positron Emission Tomography in Patients With Radioiodine-Negative Recurrent Well-Differentiated Thyroid Carcinoma. Annals of Surgery 234:6, 804-811
CrossRef318
Uwe Haberkorn, Stefan O. Schoenberg. (2001) Imaging of lung cancer with CT, MRT and PET. Lung Cancer 34, 13-23
CrossRef319
Uwe Haberkorn. (2001) Positron emission tomography (PET) of non-small cell lung cancer. Lung Cancer 34, S115-S121
CrossRef320
Michael Baumann, Georgios Stamatis, Michael Thomas. (2001) Therapy of localized non-small cell lung cancer (take home messages). Lung Cancer 33, S47-S49
CrossRef321
B Maitre. (2001) Actualités en pneumologie. La Revue de Médecine Interne 22:9, 812-818
CrossRef322
Glen A. Lillington. (2001) Lung cancer. Current Opinion in Pulmonary Medicine 7:4, 215-219
CrossRef323
Glen A. Lillington. (2001) Solitary pulmonary nodules: new wine in old bottles. Current Opinion in Pulmonary Medicine 7:4, 242-246
CrossRef324
Douglas J Mathisen. (2001) What’s new in general thoracic surgery. Journal of the American College of Surgeons 192:6, 737-749
CrossRef325
JB Bomanji, DC Costa, PJ Ell. (2001) Clinical role of positron emission tomography in oncology. The Lancet Oncology 2:3, 157-164
CrossRef326
Eeva Salminen, Michael Mac Manus. (2001) Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer. Annals of Medicine 33:6, 404-409
CrossRef327
(2000) Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography. New England Journal of Medicine 343:21, 1571-1573
Full Text328
Douglas E. Wood. (2000) Commentary on “Image-Guided Fine Needle Aspirate Strategies for Staging of Lung Cancer”. Clinical Lung Cancer 2:2, 111-112
CrossRef329
Berlangieri, Salvatore U., Scott, Andrew M., . (2000) Metabolic Staging of Lung Cancer. New England Journal of Medicine 343:4, 290-292
Full Text330
Eric K. Rowinsky. (2000) The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents. Drugs 60:Supplement 1, 1-14
CrossRef
- Letters
